CN113913393A - 新型冠状病毒肺炎的重组新城疫病毒疫苗 - Google Patents

新型冠状病毒肺炎的重组新城疫病毒疫苗 Download PDF

Info

Publication number
CN113913393A
CN113913393A CN202110628521.1A CN202110628521A CN113913393A CN 113913393 A CN113913393 A CN 113913393A CN 202110628521 A CN202110628521 A CN 202110628521A CN 113913393 A CN113913393 A CN 113913393A
Authority
CN
China
Prior art keywords
cys
gly
ala
thr
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202110628521.1A
Other languages
English (en)
Other versions
CN113913393B (zh
Inventor
步志高
葛金英
王喜军
王金良
王翀
温志远
钟功勋
帅磊
刘任强
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harbin Veterinary Research Institute of CAAS
Original Assignee
Harbin Veterinary Research Institute of CAAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harbin Veterinary Research Institute of CAAS filed Critical Harbin Veterinary Research Institute of CAAS
Priority to CN202110628521.1A priority Critical patent/CN113913393B/zh
Publication of CN113913393A publication Critical patent/CN113913393A/zh
Application granted granted Critical
Publication of CN113913393B publication Critical patent/CN113913393B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18141—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

本发明提供一种包含改造的SARS‑CoV‑2的刺突蛋白的疫苗组合物，该疫苗组合物将新城疫病毒LaSota弱毒株与新型改造的SARS‑CoV‑2的刺突蛋白(SA/SB)或(S6PA/S6PB)或其免疫原性衍生物结合构建重组新城疫病毒，用于预防新型冠状病毒的感染，尤其是针对哺乳动物的新型冠状病毒的感染。

Description

新型冠状病毒肺炎的重组新城疫病毒疫苗
技术领域
本发明涉及针对哺乳动物新型冠状病毒的预防性疫苗组合物和方法，进一步涉及针对哺乳动物新型冠状病毒的重组新城疫病毒的预防性疫苗组合物和方法。
背景技术
新型冠状病毒性疾病(COVID-19)是由新型冠状病毒(Severe Acute RespiratorySyndrome Coronavirus 2,SARS-CoV-2)引起的传播能力极强的人兽共患病。COVID-19 在全球仍然持续流行，不断危害人类生命健康。而且新型冠状病毒(SARS-CoV-2) 的动物感染谱也较为广泛，蝙蝠、水貂、雪貂、猫科动物等高度易感。目前，欧洲和北美大量养殖场水貂发生新冠病毒感染，已出现水貂将新冠病毒传播给人类的个案，近2千万只水貂被扑杀，给欧美水貂产业带来毁灭性打击，对我国的水貂产业也构成严重威胁。随着新冠肺炎(COVID-19)疫情在全球大范围人群中流行，传入易感动物的风险极大，因此迫切需要研制安全、有效的动物用新冠肺炎疫苗，阻断疫情在易感动物中传播，避免易感动物成为中间宿主或储存宿主威胁人类的卫生健康和生命安全。到目前为止仍缺少有效预防 COVID-19的方法，其中间宿主和传播途径也有待进一步证实，从而加大了防控 COVID-19的难度。疫苗是阻断、消除人间COVID-19最有效最有潜力的途径。寻找抗原性更优的SARS-CoV-2病毒的抗原依然是目前研究的热点。进一步制备用于动物的COVID-19的疫苗是阻断、消除COVID-19在动物之间以及人畜之间传播的最有效的手段。
新城疫病毒为副粘病毒，可同时诱导体液免疫、细胞免疫和粘膜免疫；LaSota 是新城疫病毒经典弱毒疫苗株，遗传相对稳定，毒株间发生重组及毒力返强可能性极小。
本发明研究人员在对SARS-CoV-2病毒抗原研究的基础上，构建了针对哺乳动物SARS-CoV-2的重组新城疫病毒载体，从而完成了本发明。
发明内容
SARS-CoV-2的刺突蛋白(Spike protein,S)是病毒受体结合蛋白和主要毒力因子之一，决定着病毒的感染谱和致病力，同时也是一个有效的免疫原，是抗 SARS-CoV-2感染过程中诱导宿主免疫反应的主要免疫原。本发明人通过专注研究冠状病毒S蛋白部分位点氨基酸的改变对S蛋白三聚体的空间构象的影响，以及Furin裂解位点的突变缺失对S蛋白空间构象的稳定性影响的研究构建了改造的SARS-CoV-2的刺突蛋白。
因此，本发明首先提供了一种包含改造的SARS-CoV-2的刺突蛋白(SA)的疫苗组合物，该改造的SARS-CoV-2的刺突蛋白(SA)包含组织型纤溶酶原激活因子信号肽(tPA)。
进一步，本发明改造的SARS-CoV-2的刺突蛋白(SA)是将S蛋白基因信号肽替换为组织型纤溶酶原激活因子信号肽(tPA)。
进一步的，该改造的SARS-CoV-2的刺突蛋白(SA)还进一步将如下6个位点氨基酸残基均突变为脯氨酸：F817P、A892P、A899P、A942P、K986P、V987P，获得改造的SARS-CoV-2的刺突蛋白(S6PA)。
在一个具体实施方案中，本发明的疫苗组合物包含改造的SARS-CoV-2的刺突蛋白(SA)，该改造的SARS-CoV-2的刺突蛋白(SA)选自命名为SA-tPA-1 (SEQ ID NO：1)的刺突蛋白,进一步SA蛋白Furin裂解位点删除，获得改造的 SARS-CoV-2的刺突蛋白(SB)选自命名为SB-tPA-1(SEQ ID NO：2)的刺突蛋白。
在一个具体实施方案中，该疫苗组合物包含改造的SARS-CoV-2的刺突蛋白(S6PA)，该改造的SARS-CoV-2的刺突蛋白(S6PA)选自命名为S6PA-tPA-1 (SEQ ID NO：3)的刺突蛋白,进一步S6PA蛋白Furin裂解位点突变缺失，获得改造的SARS-CoV-2的刺突蛋白(S6PB)选自命名为S6PB-tPA-1(SEQ ID NO： 4)的刺突蛋白。
在一个实施方案中，该改造的SARS-CoV-2的刺突蛋白(SA)或其免疫原性衍生物包含来自SEQ ID NO：1的氨基酸序列。
在一个实施方案中，该改造的SARS-CoV-2的刺突蛋白(SB)或其免疫原性衍生物包含来自SEQ ID NO：2的氨基酸序列。
在一个实施方案中，该改造的SARS-CoV-2的刺突蛋白(S6PA)或其免疫原性衍生物包含来自SEQ ID NO：3的氨基酸序列。
在一个实施方案中，该改造的SARS-CoV-2的刺突蛋白(S6PB)或其免疫原性衍生物包含来自SEQ ID NO：4的氨基酸序列。
进一步的，该改造的SARS-CoV-2的刺突蛋白(SA/SB)或(S6PA/S6PB)或其免疫原性衍生物由病毒载体编码，所述病毒载体优选新城疫病毒载体，进一步优选新城疫病毒LaSota弱毒株为载体。
其次，本发明提供一种重组新城疫病毒疫苗组合物，所述疫苗组合物包括由病毒载体编码改造的SARS-CoV-2的刺突蛋白(SA/SB)或(S6PA/S6PB)，所述病毒载体优选新城疫病毒载体，进一步优选新城疫病毒LaSota弱毒株为载体。
进一步，重组新城疫病毒被命名为重组rLa-tPA-SA或
rLa-tPA-SB，或rLa-tPA-S6PA或rLa-tPA-S6PB。
在一个具体实施方案中，本发明的疫苗组合物是口服疫苗，在另一个具体的实施方案中，本发明的疫苗组合物是亚单位疫苗.
在一个方面，本发明的疫苗组合物还包含佐剂。在一个实施方案中，佐剂选自：水包油佐剂、聚合物和水佐剂、油包水佐剂、氢氧化铝佐剂、维生素E 佐剂及其组合。在一个具体实施方案中，佐剂包含油乳剂，该油乳剂包含聚氧乙烯-聚氧丙烯嵌段共聚物、角鲨烷、聚氧乙烯山梨醇酐单油酸酯和缓冲盐溶液(SP- 油)。在一个实施方案中，本发明的疫苗组合物还包含药学上可接受的载体。
在另一个实施方案中，本发明的疫苗组合物还可以包含至少一种额外的抗原。在某些实施方案中，至少一种额外的抗原保护性地抵御可以引起哺乳动物疾病的微生物。
第三方面，本发明提供一种嵌合核酸分子，其包含编码新城疫病毒LaSota 弱毒株的核酸分子和编码改造的SARS-CoV-2的刺突蛋白(SA/SB)或(S6PA/S6PB) 的核酸分子(SEQID NO：5、SEQ ID NO：6、SEQ ID NO：7、SEQ ID NO： 8)。
第四方面，本发明还提供了保护哺乳动物免受新型冠状病毒SARS-CoV-2感染的方法。该方法包括向哺乳动物施用免疫有效量的本发明公开的疫苗组合物、嵌合核酸分子。在多种实施方案中，该方法包括通过选自经口服、胃肠道外、经鼻、皮内和经皮的一种或多于一种途径向哺乳动物施用疫苗组合物、嵌合核酸分子。在另一个实施方案中，疫苗组合物、嵌合核酸分子以单剂量施用。在另一个实施方案中，组合物与至少一种额外的抗原联合施用，该额外的抗原保护性地抵御可以引起哺乳动物疾病的微生物。
附图说明
图1：SARS-CoV-2S蛋白突变体tPAS6PB基因的设计
图2：间接免疫荧光检测tPAS6PB蛋白基因在重组新城疫病毒感染BHK细胞中的表达 (分别用重组病毒rLa-tPAS6PB和亲本株LaSota感染BHK细胞，24h后以抗SARS-CoV-2S蛋白鼠血清和抗NDV鸡血清为一抗，绿色荧光素(FITC)标记的山羊抗鼠IgG和TRITC 标记的兔抗鸡IgG为二抗，进行荧光染色。)
图3:Western blot分析SARS-CoV-2S蛋白在重组新城疫病毒感染BHK细胞中的表达 (1：蛋白质Maker；2：亲本株LaSota感染的BHK细胞；3：重组病毒rLa-tPAS6PB感染的 BHK细胞。)
图4：重组病毒rLa-tPAS6PBB对小鼠的免疫效力 (分别用重组病毒rLa-tPA6PB和亲本病毒rLaSota，按108EID50/只的剂量，间隔3周经肌肉接种途径两次免疫BALB/c小鼠。在免疫前和免疫后的不同时间点采集、分离血清用于检测SARS-CoV-2中和抗体滴度。)
图5：重组病毒rLa-tPAS6PB免疫小鼠攻毒前的中和抗体滴度 (分别随机选取6只重组病毒rLa-tPAS6PB免疫小鼠(Mouse 1～Mouse 6)和rLaSota免疫小鼠(Mouse 7～Mouse12)，用于SARS-CoV-2攻击试验。于SARS-CoV-2攻击前采集、分离血清并检测SARS-CoV-2中和抗体滴度)。
图6:重组病毒rLa-tPAS6PB免疫小鼠攻毒结果 (按103.6PFU/50μL/只的剂量，用SARS-CoV-2HRB26M株病毒经滴鼻途径攻击重组病毒 rLa-tPAS6PB免疫小鼠(Mouse 1、Mouse 2、Mouse 3、Mouse 4、Mouse 5和Mouse 6)和亲本株病毒LaSota免疫小鼠(Mouse 7、Mouse 8、Mouse9、Mouse 10、Mouse 11和Mouse 12)。攻毒后第3天和第5天，每组分别剖杀3只小鼠，用于检测小鼠鼻甲和肺脏中的SARS-CoV-2 复制、增殖情况。)
具体实施方式
虽然下面详细讨论了本发明各种实施方案的进行和使用，但应该理解，本发明提供了许多可以在各种特定情况下使用的可适用的发明概念。这里讨论的具体实施方案仅说明进行和使用本发明的具体方式，并不限制本发明的范围。
S蛋白单体情况下，RBD区存在关闭沉降和上升开放两种状态。RBD的关闭沉降状态覆盖了S2亚基部分氨基酸，削弱S蛋白的免疫原性；RBD上升开放状态则是解离S2亚基，可充分发挥其免疫原性。相较野生型S蛋白，K986P、V987P 这两个联合突变可使具有高免疫原性和可移动特性的RBD处于稳定的上升开放状态，提高表达S蛋白的免疫原性；F817P、A892P、A899P、A942P突变则可使S 蛋白的表达量增高约10倍，并具有耐热、室温贮藏和3次冻融循环的能力； SARS-CoV-2S蛋白基因的Furin裂解位点突变缺失可保留了SB蛋白的预融合构像，不裂解成S1和S2亚基，提高了SB和S6PB蛋白的抗原性。
本发明通过例举性的实施在新型冠状病毒S蛋白基因密码子优化的基础上，用组织型纤溶酶原激活因子信号肽(Tissue plasminogen activator signal sequence, tPA)基因序列替换S蛋白信号肽基因序列，同时将6个位点氨基酸残基均突变为脯氨酸(F817P、A892P、A899P、A942P、K986P、V987P)，再将S蛋白Furin 裂解位点突变缺失，人工合成新型冠状病毒S蛋白变体S6PB基因。以新城疫病毒LaSota弱毒疫苗株为疫苗载体，构建了表达新型冠状病毒S蛋白变体S6PB 基因的重组新城疫病毒LaSota弱毒疫苗株rLa-tPAS6PB。间接免疫荧光和Western blot试验结果证实：S蛋白突变体S6PB基因在重组新城疫病毒rLa-tPAS6PB感染的细胞中获得正确表达，表达的S6PB蛋白具有良好的反应原性。。
为了便于理解本发明，下面定义了许多术语。本发明定义的术语具有本发明相关领域中普通技术人员通常理解的含义。
如本发明所用术语“包含”、“包括”、“含有”旨在表示组合物和方法包括所列举的要素，但不排除其他要素。
术语“抗原”是指可以在动物中刺激抗体或T细胞应答或两者的产生的化合物、组合物或免疫原性物质，其包括口服、注射或吸收到动物体内的组合物。可以对整个分子或分子的一部分(例如表位或半抗原)产生免疫应答。
如本发明所定义的，“免疫原性组合物或免疫组合物”是指包含至少一种抗原的物质的组合物，该抗原在宿主中引发对感兴趣的组合物或疫苗的细胞的免疫应答和/或抗体介导的免疫应答。
本发明所用的“佐剂”是指由一种或多于一种增强对抗原的免疫应答的物质组成的组合物。佐剂如何起作用的机制尚不完全清楚。一些佐剂被认为通过缓慢释放抗原来增强免疫应答，而其他佐剂本身具有强免疫原性并被认为起到协同作用。
本发明所用的术语“哺乳动物”是指包括人、及对新型冠状病毒易感的哺乳动物，例如人、蝙蝠、狮子、老虎、恒河猴、食蟹猴、水貂、雪貂、猫、狗等。
如本文所用术语“药学上可接受的载体”是指用于包含可以口服或注射到宿主中且没有副作用的疫苗抗原的流体载体。本领域已知的合适的药学上可接受的载体包括但不限于无菌水、盐水、葡萄糖、右旋糖或缓冲溶液等。载体可包括助剂包括但不限于稀释剂、稳定剂(糖和氨基酸)、防腐剂、润湿剂、乳化剂、pH 缓冲剂、黏度增强添加剂、着色剂等。
如本文所用术语“疫苗组合物”包括在药学上可接受的载体中的至少一种抗原或免疫原，其可用于在宿主中诱导免疫应答。疫苗组合物可以按剂量施用并通过医学或兽医领域技术人员熟知的技术施用，同时考虑例如接受体动物的年龄、性别、体重、物种和状况、以及给药途径等因素。给药途径可以是经皮(通过皮内、经皮、皮下、肌内途径而穿过皮肤或通过口腔、鼻腔、肛门、阴道而穿过黏膜)或通过肠胃外途径(静脉内或腹膜内)。疫苗组合物可以单独施用，或者可以与其他治疗或疗法共同施用或按顺序施用。给药形式可包括混悬剂、糖浆剂或酏剂，以及用于肠胃外、皮下、皮内、肌内或静脉内给药(例如注射给药)的制剂，例如无菌混悬剂或乳剂。疫苗组合物可以以喷雾形式给药或混合于食物和/或水中或与合适的载体、稀释剂、或赋形剂如无菌水、生理盐水、葡萄糖等混合递送。该组合物可含有辅助物质，如润湿剂或乳化剂、pH缓冲剂、佐剂、凝胶化或黏度增强添加剂、防腐剂、调味剂、着色剂等，这取决于给药途径和所需制剂。
为了公开的完整性，包括了以下实施例以说明制备本发明组合物和复合物的方法以及呈现组合物的某些特征。这些实施例决不旨在限制本公开的范围或教导。
实施例1：材料与方法
1.1病毒株
新城疫病毒LaSota弱毒疫苗株反向遗传操作系统由中国农业科学院哈尔滨兽医研究所重要人兽共患病与烈性外来病创新团队建立并保存；SARS-CoV-2小鼠适应株HRB26M是由中国农业科学院国家动物疫病防控高级别生物安全实验室保存。
1.2细胞
BHK细胞(ATCC No.CCL-10)由中国农业科学院哈尔滨兽医研究所重要人兽共患病与烈性外来病创新团队保存、培养。BHK细胞培养液为含10％胎牛血清的DMEM。
1.3质粒与试剂
NDV LaSota全基因组克隆质粒pBRN-FL及辅助质粒pBS-NP、pBS-P、pBS-L 由中国农业科学院哈尔滨兽医研究所重要人兽共患病与烈性外来病创新团队构建、保存。高保真DNA聚合酶(Phanta Max Super-Fidelity DNA Polymerase)、快速克隆试剂盒(ClonExpress Ultra One Step Cloning Kit)购自南京诺维赞生物科技股份有限公司。X-tremeGENETM9DNA转染试剂购自Merck公司。抗 SARS-CoV-2S蛋白多克隆抗体、抗SARS-CoV-2S蛋白单克隆抗体由中国农业科学院哈尔滨兽医研究所重要人兽共患病与烈性外来病创新团队制备。绿色荧光素(FITC)标记的山羊抗鼠IgG购自北京中杉金桥生物技术有限公司。红外荧光标记的驴抗鼠IgG购自Life technologies公司。胎牛血清，Opti-MEM均购自Gbico公司；FITC标记的兔抗鸡IgG抗体、TRITC标记的山羊抗鼠IgG抗体、辣根过氧化物酶(HRP)标记的山羊抗小鼠IgG和HRP标记兔抗鸡IgG均购自 Sigma公司。
按人工合成的方法合成SARS-CoV-2S蛋白突变体tPAS6PB(S6PB)基因，并将其克隆至pBluescript II(+/-)(Clontech)的EcoR V位点，命名为pBlue-tPAS6PB。 S6PB基因是在SARS-CoV-2S蛋白基因按哺乳动物密码子偏嗜性进行优化的基础上，将该蛋白基因2449-2451位、2674-2676位、2695-2697位、2824-2826位、 2956-2958位和2959-2961位碱基均突变为“CCC”，由此将上述碱基编码的第817 位苯丙氨酸(Phenylalanine,Phe,F)、第892位丙氨酸(Alanine,Ala,A)、第899 位丙氨酸(Alanine,Ala,A)、第942位丙氨酸(Alanine,Ala,A)、第986位赖氨酸(Lysine,Lys,K)和第987位缬氨酸(Valine,Val,V)均突变为脯氨酸(Proline, Pro,P)；将SARS-CoV-2S蛋白裂解位点基因2044-2055位碱基突变为“GGCTCCGCCTCC”，由此裂解位点氨基酸由“RRAR”突变为“GSAS”[精氨酸 (Arginine,Arg,R)，甘氨酸(Glycine,Gly,G)丝氨酸(Serine,Ser,S)]；同时用组织型纤溶酶原激活因子(Tissue plasminogen activator,tPA)的信号肽基因替代SARS-CoV-2S蛋白信号肽基因构成S6P基因(图1)；在S6P基因的起始密码子ATG前插入Kozak序列“GCCGCCACC”。
1.4引物设计与合成
根据tPAS6PB蛋白基因序列、以NDV病毒LaSota基因组插入位点PmeI序列为同源臂，设计了构建表达tPAS6PB蛋白基因的重组NDV全长质粒的同源重组引物(表2)。
表2表达SARS-CoV-2 tPAS6PB基因重组NDV全基因组质粒所用引物
Figure RE-GDA0003363112260000081
1.5表达tPAS6PB蛋白基因重组新城疫病毒的构建
用限制性内切酶PmeⅠ酶切、线性化pBRN-FL，胶回收纯化线性载体。采用PCR方法，以pBlue-tPAS6PB为模板，用引物NDV-tpaOS6PB-PF和 NDV-optS-tpa-PR扩增tPAS6PB基因，胶回收纯化tPAS6PB基因。利用快速克隆试剂盒，将tPAS6PB蛋白基因顺序克隆至载体pBRN-FL的PmeⅠ位点，构成含有tPAS6PB蛋白基因的重组全基因组克隆质粒pBRN-FL-tPAS6PB。
BHK细胞接种于35mm六孔板中，待过夜生长至80％～90％单层时，分别用稳定表达T7聚合酶的重组痘病毒vTF-3，按M.O.I约0.01的剂量，感染过BHK 细胞，5％CO2、37℃环境感作1小时后，更换新鲜的完全培养基。重组质粒 pBRN-FL-tPAS6PB及辅助质粒pBS-NP、pBS-P、pBS-L，采用脂质体转染的方法共转染BHK细胞。转染8～12h后，换成新鲜的完全培养基，然后每孔加入阿拉伯糖苷(10μg/mL)，37℃孵育24h后换成Opti-MEM，并加入阿拉伯糖苷和TPCK(1μg/mL)。37℃继续孵育72h后，收获培养物上清，接种于9～ 10日龄SPF鸡胚尿囊腔中。5d后，取尿囊液进行新城疫病毒的血凝试验(HA) 和血凝抑制试验(HI)。收获HA和HI均呈阳性结果的尿囊液，分装后-70℃冻存，重组病毒命名为rLa-tPAS6PB。
1.6间接免疫荧光检测
重组病毒rLa-tPAS6PB按照M.O.I为0.01的量感染生长于24孔板中的BHK 细胞，并接种亲本株LaSota做为对照。细胞培养24h后用冰冷3％多聚甲醛固定，分别以1:100倍稀释抗SARS-CoV-2S蛋白小鼠血清和鸡抗NDV高免血清为一抗，以SPF鸡阴性血清为阴性对照；以荧光素(FITC)标记的山羊抗鼠IgG 和荧光素(TRITC)标记的兔抗鸡IgG(Sigma)为二抗，共聚焦法进行IFA检测。
1.7Western bloting
取重组病毒rLa-tPAS6PB，过量感染BHK细胞，72h后收集细胞，裂解细胞产物进行SDS-PAGE，再转印至NC膜上。NC膜用含3％BSA的PBS溶液于4℃封闭过夜。分别以1：100稀释的鸡抗NDV多抗和1：100倍稀释的抗SARS-CoV-2 S蛋白小鼠血清为一抗，红外荧光标记的驴抗鼠IgG和山羊抗鸡IgG为二抗，通过Odyssey Infrared成像系统成像并分析各重组新城疫病毒的蛋白表达情况。
1.8重组病毒rLa-tPAS6PB对BALB/c小鼠的免疫试验
为了评估表达SARS-CoV-2S蛋白的重组病毒rLa-tPAS6PB在小鼠上的免疫效力，取6周龄雌性BALB/c小鼠10只，用重组病毒rLa-tPAS6PB按3×108 EID50/100μL/只的剂量经肌肉注射途径免疫小鼠，间隔3周免疫接种两次，以亲本株LaSota免疫小鼠作为对照组。在小鼠免疫前、初次免疫后第3周和第5周经眶下静脉丛采血，分离血清，同组小鼠同一时间点的血清混合后，在56℃水浴灭活30min，用病毒中和实验法检测SARS-CoV-2中和抗体。
1.9重组新城疫病毒rLa-tPAS6PB对BALB/c小鼠的攻毒保护效力试验
初次免疫后第6周，重组疫苗免疫小鼠和对照小鼠经眶下静脉丛采血，分离血清，用于SARS-CoV-2中和抗体检测。同时，按103.6PFU/50μL/只的剂量，用 SARS-CoV-2HRB26M株病毒经滴鼻途径接种。攻毒后第3天和第5天，每组各剖解3只小鼠，采集鼻甲和肺脏，用实时荧光定量PCR的方法进行病毒载量检测。
1.10中和试验
检测血清中SARS-CoV-2中和抗体的中和试验在96孔板上进行，步骤如下：首先将血清样品置于56℃水浴30min进行灭活，再将血清样品分别以不完全 DMEM连续倍比稀释，每稀释度体积为50μL，与50μL约含100PFU的 SARS-CoV-2HRB25株病毒液混合，37℃感作1h后，每孔加入约105Vero E6 细胞，5％CO2、37℃培养48h后，置于显微镜下观察SARS-CoV-2HRB25株病毒感染形成的蚀斑情况。每个血清稀释度做4个重复。血清中SARS-CoV-2中和抗体滴度被定义为能抑制50％蚀斑产生的最高血清稀释倍数。
1.11实时荧光定量PCR
采用实时荧光定量PCR方法测定组织样品中的病毒载量。针对 SARS-CoV-2N基因的实时荧光定量PCR特异性引物和荧光探针均参照中国疾病预防控制中心病毒病预防控制所发布的信息(http://nmdc.cn/nCoV)，具体如下：上游引物：5’-GGG GAA CTT CTC CTGCTA GAA T-3’；下游引物,5’-CAG ACA TTT TGC TCT CAA GCT G-3’，荧光探针为：5’-FAM-TTG CTG CTG CTT GAC AGA TT-TAMRA-3’。利用病毒RNA提取试剂盒QIAampvRNAMinikit(Qiagen) 提取病毒RNA后，应用HiScript II Q RT SuperMix for qPCR(Vazyme)试剂盒进行反转录，再应用DNA聚合酶Premix Ex Taq for probe qPCR(TaRaKa,China)，在实时荧光定量PCR仪(Applied BiosystemsQuantStudio 5Real-Time PCR System, ThermoScientific)上进行qPCR。SARS-CoV-2RNA的拷贝数是通过利用质粒 pBluescript II SK-N(将全长的SARS-CoV-2N基因克隆到pBluescript II SK上构成)绘制的标准曲线进行计算、校正。该qPCR方法的检测下限为1000拷贝/mL。
实施例2：实验结果
2.1表达S6PB蛋白基因重组新城疫病毒的构建
根据成基因tPAS6PB序列信息，利用引物在tPAS6PB基因末端引入酶切位点和基因调控序列。用同源重组引物合成基因片段，与同样经Pme I处理的载体 pBRN-FL-PmeI进行同源重组克隆，获得表达tPAS6PB基因重组新城疫病毒全长cDNA克隆pBRN-FL-tPAS6PB。
将pBRN-FL-tPAS6PB与辅助质粒pBS-NP、pBS-P、pBS-L共转染BHK细胞，获得血凝试验(HA)和血凝抑制试验(HI)阳性的重组病毒rLa-tPAS6PB。以特异性引物对重组病毒进行RT-PCR检测并测序，结果所获PCR产物序列与预期目的片段相符，证明tPAS6PB基因成功插入重组病毒基因组。
2.2间接免疫荧光检测救获的重组病毒
拯救的重组病毒rLa-tPAS6PB以MOI为0.01感染BHK细胞，同时设定LaSota接种细胞作为阴性对照。接种细胞37℃培养24h后共聚焦法进行间接免疫荧光检测，结果显示重组病毒组呈现SARS-CoV-2S蛋白和NDV蛋白的共表达，LaSota对照细胞仅呈现针对NDV抗体的阳性结果(图2)。
2.3Western bloting
蛋白样品经电泳转印后，重组病毒rLa-tPAS6PB接种的细胞样品以鼠抗 SARS-CoV-2和鸡抗NDV高免血清为一抗进行WB检测。结果相比较LaSota对照细胞样品，rLa-tPAS6PB接种的细胞样品出现特异性条带，与相应外源蛋白预期大小相符。以鸡抗NDV为一抗的WB检测结果中，两个样品泳道上均出现 NDV特异性条带(图3)。Western blot检测结果说明tPAS6PB蛋白在重组病毒中得到了正确表达，并具有良好的反应原性。
2.4重组病毒对小鼠的免疫效力
为了评估重组新城疫病毒rLa-tPAS6PB对小鼠的免疫原性，用重组病毒 rLa-tPAS6PB经肌肉注射途径免疫小鼠10只，并间隔3周进行加强免疫。结果显示：初次免疫后3周，即可在重组病毒rLa-tPAS6PB免疫接种的小鼠血清中能检测到SARS-CoV-2中和抗体，抗体滴度为32。而免疫对照小鼠血清中则检测不到SARS-CoV-2中和抗体。第二次免疫后2周，rMVA-tPAS6PB免疫小鼠血清中SARS-CoV-2中和抗体滴度上升至512。结果表明，重组病毒rLa-tPAS6PB具备成为动物用新冠肺炎活载体疫苗的潜力(图4)。
2.5重组病毒对小鼠的攻毒保护效力
为了评估表达SARS-CoV-2S蛋白基因的重组新城疫病毒rLa-tPAS6PB对小鼠的保护效力，初次免疫后15周，随机各选取6只重组病毒rLa-tPAS6PB免疫接种小鼠和rLaSota免疫接种小鼠，用于SARS-CoV-2攻击试验。攻毒前对rLaSota 免疫接种小鼠血清中仍然检测不到SARS-CoV-2中和抗体，而小鼠血清中 SARS-CoV-2中和抗体进行检测(图5)。rLa-tPAS6PB免疫接种小鼠血清中可检测到高水平的SARS-CoV-2中和抗体，滴度分别为128，256，64，32，128和 64。
rLa-tPAS6PB免疫小鼠和亲本株rLaSota免疫接种小鼠用SARS-CoV-2 HRB26M株病毒经滴鼻途径攻击。攻毒后第3天，亲本株rLaSota接种小鼠的鼻甲和肺脏均能检测到高拷贝的病毒核酸和高滴度的SARS-CoV-2活病毒；而3只 rLa-tPAS6PB免疫小鼠中有1只的鼻夹和肺脏均可检测到病毒核酸，但其鼻甲病毒分离滴定的结果仍低于对照组小鼠，肺部病毒分离结果为阴性；另外2只其中 1只鼻甲检测到病毒核酸，拷贝数稍低于对照组小鼠的检测结果，另外1只肺检测到病毒核酸，但拷贝数显著低于亲本株rLaSota接种对照组小鼠，这2只小鼠的鼻甲和肺均分离不到活病毒。攻毒后第5天，亲本株rLaSota接种小鼠的鼻甲和肺脏仍能检测到高拷贝的病毒核酸和高滴度的活病毒；而3只rLa-tPAS6PB免疫小鼠鼻甲和肺脏均检测不到病毒核酸，活病毒分离结果也全部为阴性(图6)。结果表明，重组病毒rLa-tPAS6PB免疫小鼠诱导产生了良好的中和抗体反应，并效清除了小鼠体内的SARS-CoV-2活病毒。
以上结果表明，重组新城疫病毒rLa-tPAS6PB具有良好的免疫原性和攻毒保护效力，能够成为动物用新型冠状病毒肺炎疫苗而且重组新城疫病毒rLa-tPAS6PB具有良好的安全性、口服免疫原性和攻毒保护效力。
序列表
<110> 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心)
<120> 新型冠状病毒肺炎的重组新城疫病毒疫苗
<160> 8
<170> SIPOSequenceListing 1.0
<210> 1
<211> 1283
<212> PRT
<213> 重组蛋白()
<400> 1
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15
Ala Val Phe Val Ser Ala Arg Gln Cys Val Asn Leu Thr Thr Arg Thr
20 25 30
Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe Thr Arg Gly Val Tyr Tyr
35 40 45
Pro Asp Lys Val Phe Arg Ser Ser Val Leu His Ser Thr Gln Asp Leu
50 55 60
Phe Leu Pro Phe Phe Ser Asn Val Thr Trp Phe His Ala Ile His Val
65 70 75 80
Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp Asn Pro Val Leu Pro Phe
85 90 95
Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu Lys Ser Asn Ile Ile Arg
100 105 110
Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser Lys Thr Gln Ser Leu Leu
115 120 125
Ile Val Asn Asn Ala Thr Asn Val Val Ile Lys Val Cys Glu Phe Gln
130 135 140
Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr Tyr His Lys Asn Asn Lys
145 150 155 160
Ser Trp Met Glu Ser Glu Phe Arg Val Tyr Ser Ser Ala Asn Asn Cys
165 170 175
Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu Met Asp Leu Glu Gly Lys
180 185 190
Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe Val Phe Lys Asn Ile Asp
195 200 205
Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr Pro Ile Asn Leu Val Arg
210 215 220
Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu Pro Leu Val Asp Leu Pro
225 230 235 240
Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr Leu Leu Ala Leu His Arg
245 250 255
Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser Gly Trp Thr Ala Gly Ala
260 265 270
Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro Arg Thr Phe Leu Leu Lys
275 280 285
Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala Val Asp Cys Ala Leu Asp
290 295 300
Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys Ser Phe Thr Val Glu Lys
305 310 315 320
Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val Gln Pro Thr Glu Ser Ile
325 330 335
Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe
340 345 350
Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile
355 360 365
Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe
370 375 380
Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu
385 390 395 400
Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu
405 410 415
Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn
420 425 430
Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser
435 440 445
Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg
450 455 460
Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr
465 470 475 480
Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe
485 490 495
Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly
500 505 510
Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu
515 520 525
His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val
530 535 540
Lys Asn Lys Cys Val Asn Phe Asn Phe Asn Gly Leu Thr Gly Thr Gly
545 550 555 560
Val Leu Thr Glu Ser Asn Lys Lys Phe Leu Pro Phe Gln Gln Phe Gly
565 570 575
Arg Asp Ile Ala Asp Thr Thr Asp Ala Val Arg Asp Pro Gln Thr Leu
580 585 590
Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe Gly Gly Val Ser Val Ile
595 600 605
Thr Pro Gly Thr Asn Thr Ser Asn Gln Val Ala Val Leu Tyr Gln Asp
610 615 620
Val Asn Cys Thr Glu Val Pro Val Ala Ile His Ala Asp Gln Leu Thr
625 630 635 640
Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser Asn Val Phe Gln Thr Arg
645 650 655
Ala Gly Cys Leu Ile Gly Ala Glu His Val Asn Asn Ser Tyr Glu Cys
660 665 670
Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Tyr Gln Thr Gln Thr
675 680 685
Asn Ser Pro Arg Arg Ala Arg Ser Val Ala Ser Gln Ser Ile Ile Ala
690 695 700
Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser Val Ala Tyr Ser Asn Asn
705 710 715 720
Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile Ser Val Thr Thr Glu Ile
725 730 735
Leu Pro Val Ser Met Thr Lys Thr Ser Val Asp Cys Thr Met Tyr Ile
740 745 750
Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu Leu Leu Gln Tyr Gly Ser
755 760 765
Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr Gly Ile Ala Val Glu Gln
770 775 780
Asp Lys Asn Thr Gln Glu Val Phe Ala Gln Val Lys Gln Ile Tyr Lys
785 790 795 800
Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe Asn Phe Ser Gln Ile Leu
805 810 815
Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser Phe Ile Glu Asp Leu Leu
820 825 830
Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Ile Lys Gln Tyr Gly
835 840 845
Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp Leu Ile Cys Ala Gln Lys
850 855 860
Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr Asp Glu Met Ile
865 870 875 880
Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly Thr Ile Thr Ser Gly Trp
885 890 895
Thr Phe Gly Ala Gly Ala Ala Leu Gln Ile Pro Phe Ala Met Gln Met
900 905 910
Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn Val Leu Tyr Glu
915 920 925
Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn Ser Ala Ile Gly Lys Ile
930 935 940
Gln Asp Ser Leu Ser Ser Thr Ala Ser Ala Leu Gly Lys Leu Gln Asp
945 950 955 960
Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu Val Lys Gln Leu
965 970 975
Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn Asp Ile Leu Ser
980 985 990
Arg Leu Asp Lys Val Glu Ala Glu Val Gln Ile Asp Arg Leu Ile Thr
995 1000 1005
Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg
1010 1015 1020
Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala Thr Lys Met Ser
1025 1030 1035 1040
Glu Cys Val Leu Gly Gln Ser Lys Arg Val Asp Phe Cys Gly Lys Gly
1045 1050 1055
Tyr His Leu Met Ser Phe Pro Gln Ser Ala Pro His Gly Val Val Phe
1060 1065 1070
Leu His Val Thr Tyr Val Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala
1075 1080 1085
Pro Ala Ile Cys His Asp Gly Lys Ala His Phe Pro Arg Glu Gly Val
1090 1095 1100
Phe Val Ser Asn Gly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr
1105 1110 1115 1120
Glu Pro Gln Ile Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys
1125 1130 1135
Asp Val Val Ile Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln
1140 1145 1150
Pro Glu Leu Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn
1155 1160 1165
His Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala
1170 1175 1180
Ser Val Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala
1185 1190 1195 1200
Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr
1205 1210 1215
Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Ile Trp Leu Gly Phe Ile Ala
1220 1225 1230
Gly Leu Ile Ala Ile Val Met Val Thr Ile Met Leu Cys Cys Met Thr
1235 1240 1245
Ser Cys Cys Ser Cys Leu Lys Gly Cys Cys Ser Cys Gly Ser Cys Cys
1250 1255 1260
Lys Phe Asp Glu Asp Asp Ser Glu Pro Val Leu Lys Gly Val Lys Leu
1265 1270 1275 1280
His Tyr Thr
<210> 2
<211> 1279
<212> PRT
<213> 重组蛋白()
<400> 2
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15
Ala Val Phe Val Ser Ala Arg Gln Cys Val Asn Leu Thr Thr Arg Thr
20 25 30
Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe Thr Arg Gly Val Tyr Tyr
35 40 45
Pro Asp Lys Val Phe Arg Ser Ser Val Leu His Ser Thr Gln Asp Leu
50 55 60
Phe Leu Pro Phe Phe Ser Asn Val Thr Trp Phe His Ala Ile His Val
65 70 75 80
Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp Asn Pro Val Leu Pro Phe
85 90 95
Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu Lys Ser Asn Ile Ile Arg
100 105 110
Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser Lys Thr Gln Ser Leu Leu
115 120 125
Ile Val Asn Asn Ala Thr Asn Val Val Ile Lys Val Cys Glu Phe Gln
130 135 140
Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr Tyr His Lys Asn Asn Lys
145 150 155 160
Ser Trp Met Glu Ser Glu Phe Arg Val Tyr Ser Ser Ala Asn Asn Cys
165 170 175
Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu Met Asp Leu Glu Gly Lys
180 185 190
Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe Val Phe Lys Asn Ile Asp
195 200 205
Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr Pro Ile Asn Leu Val Arg
210 215 220
Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu Pro Leu Val Asp Leu Pro
225 230 235 240
Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr Leu Leu Ala Leu His Arg
245 250 255
Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser Gly Trp Thr Ala Gly Ala
260 265 270
Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro Arg Thr Phe Leu Leu Lys
275 280 285
Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala Val Asp Cys Ala Leu Asp
290 295 300
Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys Ser Phe Thr Val Glu Lys
305 310 315 320
Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val Gln Pro Thr Glu Ser Ile
325 330 335
Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe
340 345 350
Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile
355 360 365
Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe
370 375 380
Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu
385 390 395 400
Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu
405 410 415
Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn
420 425 430
Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser
435 440 445
Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg
450 455 460
Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr
465 470 475 480
Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe
485 490 495
Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly
500 505 510
Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu
515 520 525
His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val
530 535 540
Lys Asn Lys Cys Val Asn Phe Asn Phe Asn Gly Leu Thr Gly Thr Gly
545 550 555 560
Val Leu Thr Glu Ser Asn Lys Lys Phe Leu Pro Phe Gln Gln Phe Gly
565 570 575
Arg Asp Ile Ala Asp Thr Thr Asp Ala Val Arg Asp Pro Gln Thr Leu
580 585 590
Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe Gly Gly Val Ser Val Ile
595 600 605
Thr Pro Gly Thr Asn Thr Ser Asn Gln Val Ala Val Leu Tyr Gln Asp
610 615 620
Val Asn Cys Thr Glu Val Pro Val Ala Ile His Ala Asp Gln Leu Thr
625 630 635 640
Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser Asn Val Phe Gln Thr Arg
645 650 655
Ala Gly Cys Leu Ile Gly Ala Glu His Val Asn Asn Ser Tyr Glu Cys
660 665 670
Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Tyr Gln Thr Gln Thr
675 680 685
Asn Ser Pro Ser Val Ala Ser Gln Ser Ile Ile Ala Tyr Thr Met Ser
690 695 700
Leu Gly Ala Glu Asn Ser Val Ala Tyr Ser Asn Asn Ser Ile Ala Ile
705 710 715 720
Pro Thr Asn Phe Thr Ile Ser Val Thr Thr Glu Ile Leu Pro Val Ser
725 730 735
Met Thr Lys Thr Ser Val Asp Cys Thr Met Tyr Ile Cys Gly Asp Ser
740 745 750
Thr Glu Cys Ser Asn Leu Leu Leu Gln Tyr Gly Ser Phe Cys Thr Gln
755 760 765
Leu Asn Arg Ala Leu Thr Gly Ile Ala Val Glu Gln Asp Lys Asn Thr
770 775 780
Gln Glu Val Phe Ala Gln Val Lys Gln Ile Tyr Lys Thr Pro Pro Ile
785 790 795 800
Lys Asp Phe Gly Gly Phe Asn Phe Ser Gln Ile Leu Pro Asp Pro Ser
805 810 815
Lys Pro Ser Lys Arg Ser Phe Ile Glu Asp Leu Leu Phe Asn Lys Val
820 825 830
Thr Leu Ala Asp Ala Gly Phe Ile Lys Gln Tyr Gly Asp Cys Leu Gly
835 840 845
Asp Ile Ala Ala Arg Asp Leu Ile Cys Ala Gln Lys Phe Asn Gly Leu
850 855 860
Thr Val Leu Pro Pro Leu Leu Thr Asp Glu Met Ile Ala Gln Tyr Thr
865 870 875 880
Ser Ala Leu Leu Ala Gly Thr Ile Thr Ser Gly Trp Thr Phe Gly Ala
885 890 895
Gly Ala Ala Leu Gln Ile Pro Phe Ala Met Gln Met Ala Tyr Arg Phe
900 905 910
Asn Gly Ile Gly Val Thr Gln Asn Val Leu Tyr Glu Asn Gln Lys Leu
915 920 925
Ile Ala Asn Gln Phe Asn Ser Ala Ile Gly Lys Ile Gln Asp Ser Leu
930 935 940
Ser Ser Thr Ala Ser Ala Leu Gly Lys Leu Gln Asp Val Val Asn Gln
945 950 955 960
Asn Ala Gln Ala Leu Asn Thr Leu Val Lys Gln Leu Ser Ser Asn Phe
965 970 975
Gly Ala Ile Ser Ser Val Leu Asn Asp Ile Leu Ser Arg Leu Asp Lys
980 985 990
Val Glu Ala Glu Val Gln Ile Asp Arg Leu Ile Thr Gly Arg Leu Gln
995 1000 1005
Ser Leu Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg Ala Ala Glu Ile
1010 1015 1020
Arg Ala Ser Ala Asn Leu Ala Ala Thr Lys Met Ser Glu Cys Val Leu
1025 1030 1035 1040
Gly Gln Ser Lys Arg Val Asp Phe Cys Gly Lys Gly Tyr His Leu Met
1045 1050 1055
Ser Phe Pro Gln Ser Ala Pro His Gly Val Val Phe Leu His Val Thr
1060 1065 1070
Tyr Val Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala Pro Ala Ile Cys
1075 1080 1085
His Asp Gly Lys Ala His Phe Pro Arg Glu Gly Val Phe Val Ser Asn
1090 1095 1100
Gly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr Glu Pro Gln Ile
1105 1110 1115 1120
Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys Asp Val Val Ile
1125 1130 1135
Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln Pro Glu Leu Asp
1140 1145 1150
Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn His Thr Ser Pro
1155 1160 1165
Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala Ser Val Val Asn
1170 1175 1180
Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala Lys Asn Leu Asn
1185 1190 1195 1200
Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr Glu Gln Tyr Ile
1205 1210 1215
Lys Trp Pro Trp Tyr Ile Trp Leu Gly Phe Ile Ala Gly Leu Ile Ala
1220 1225 1230
Ile Val Met Val Thr Ile Met Leu Cys Cys Met Thr Ser Cys Cys Ser
1235 1240 1245
Cys Leu Lys Gly Cys Cys Ser Cys Gly Ser Cys Cys Lys Phe Asp Glu
1250 1255 1260
Asp Asp Ser Glu Pro Val Leu Lys Gly Val Lys Leu His Tyr Thr
1265 1270 1275
<210> 3
<211> 1283
<212> PRT
<213> 重组蛋白()
<400> 3
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15
Ala Val Phe Val Ser Ala Arg Gln Cys Val Asn Leu Thr Thr Arg Thr
20 25 30
Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe Thr Arg Gly Val Tyr Tyr
35 40 45
Pro Asp Lys Val Phe Arg Ser Ser Val Leu His Ser Thr Gln Asp Leu
50 55 60
Phe Leu Pro Phe Phe Ser Asn Val Thr Trp Phe His Ala Ile His Val
65 70 75 80
Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp Asn Pro Val Leu Pro Phe
85 90 95
Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu Lys Ser Asn Ile Ile Arg
100 105 110
Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser Lys Thr Gln Ser Leu Leu
115 120 125
Ile Val Asn Asn Ala Thr Asn Val Val Ile Lys Val Cys Glu Phe Gln
130 135 140
Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr Tyr His Lys Asn Asn Lys
145 150 155 160
Ser Trp Met Glu Ser Glu Phe Arg Val Tyr Ser Ser Ala Asn Asn Cys
165 170 175
Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu Met Asp Leu Glu Gly Lys
180 185 190
Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe Val Phe Lys Asn Ile Asp
195 200 205
Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr Pro Ile Asn Leu Val Arg
210 215 220
Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu Pro Leu Val Asp Leu Pro
225 230 235 240
Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr Leu Leu Ala Leu His Arg
245 250 255
Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser Gly Trp Thr Ala Gly Ala
260 265 270
Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro Arg Thr Phe Leu Leu Lys
275 280 285
Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala Val Asp Cys Ala Leu Asp
290 295 300
Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys Ser Phe Thr Val Glu Lys
305 310 315 320
Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val Gln Pro Thr Glu Ser Ile
325 330 335
Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe
340 345 350
Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile
355 360 365
Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe
370 375 380
Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu
385 390 395 400
Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu
405 410 415
Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn
420 425 430
Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser
435 440 445
Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg
450 455 460
Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr
465 470 475 480
Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe
485 490 495
Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly
500 505 510
Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu
515 520 525
His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val
530 535 540
Lys Asn Lys Cys Val Asn Phe Asn Phe Asn Gly Leu Thr Gly Thr Gly
545 550 555 560
Val Leu Thr Glu Ser Asn Lys Lys Phe Leu Pro Phe Gln Gln Phe Gly
565 570 575
Arg Asp Ile Ala Asp Thr Thr Asp Ala Val Arg Asp Pro Gln Thr Leu
580 585 590
Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe Gly Gly Val Ser Val Ile
595 600 605
Thr Pro Gly Thr Asn Thr Ser Asn Gln Val Ala Val Leu Tyr Gln Asp
610 615 620
Val Asn Cys Thr Glu Val Pro Val Ala Ile His Ala Asp Gln Leu Thr
625 630 635 640
Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser Asn Val Phe Gln Thr Arg
645 650 655
Ala Gly Cys Leu Ile Gly Ala Glu His Val Asn Asn Ser Tyr Glu Cys
660 665 670
Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Tyr Gln Thr Gln Thr
675 680 685
Asn Ser Pro Arg Arg Ala Arg Ser Val Ala Ser Gln Ser Ile Ile Ala
690 695 700
Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser Val Ala Tyr Ser Asn Asn
705 710 715 720
Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile Ser Val Thr Thr Glu Ile
725 730 735
Leu Pro Val Ser Met Thr Lys Thr Ser Val Asp Cys Thr Met Tyr Ile
740 745 750
Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu Leu Leu Gln Tyr Gly Ser
755 760 765
Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr Gly Ile Ala Val Glu Gln
770 775 780
Asp Lys Asn Thr Gln Glu Val Phe Ala Gln Val Lys Gln Ile Tyr Lys
785 790 795 800
Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe Asn Phe Ser Gln Ile Leu
805 810 815
Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser Pro Ile Glu Asp Leu Leu
820 825 830
Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Ile Lys Gln Tyr Gly
835 840 845
Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp Leu Ile Cys Ala Gln Lys
850 855 860
Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr Asp Glu Met Ile
865 870 875 880
Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly Thr Ile Thr Ser Gly Trp
885 890 895
Thr Phe Gly Ala Gly Pro Ala Leu Gln Ile Pro Phe Pro Met Gln Met
900 905 910
Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn Val Leu Tyr Glu
915 920 925
Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn Ser Ala Ile Gly Lys Ile
930 935 940
Gln Asp Ser Leu Ser Ser Thr Pro Ser Ala Leu Gly Lys Leu Gln Asp
945 950 955 960
Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu Val Lys Gln Leu
965 970 975
Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn Asp Ile Leu Ser
980 985 990
Arg Leu Asp Pro Pro Glu Ala Glu Val Gln Ile Asp Arg Leu Ile Thr
995 1000 1005
Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg
1010 1015 1020
Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala Thr Lys Met Ser
1025 1030 1035 1040
Glu Cys Val Leu Gly Gln Ser Lys Arg Val Asp Phe Cys Gly Lys Gly
1045 1050 1055
Tyr His Leu Met Ser Phe Pro Gln Ser Ala Pro His Gly Val Val Phe
1060 1065 1070
Leu His Val Thr Tyr Val Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala
1075 1080 1085
Pro Ala Ile Cys His Asp Gly Lys Ala His Phe Pro Arg Glu Gly Val
1090 1095 1100
Phe Val Ser Asn Gly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr
1105 1110 1115 1120
Glu Pro Gln Ile Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys
1125 1130 1135
Asp Val Val Ile Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln
1140 1145 1150
Pro Glu Leu Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn
1155 1160 1165
His Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala
1170 1175 1180
Ser Val Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala
1185 1190 1195 1200
Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr
1205 1210 1215
Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Ile Trp Leu Gly Phe Ile Ala
1220 1225 1230
Gly Leu Ile Ala Ile Val Met Val Thr Ile Met Leu Cys Cys Met Thr
1235 1240 1245
Ser Cys Cys Ser Cys Leu Lys Gly Cys Cys Ser Cys Gly Ser Cys Cys
1250 1255 1260
Lys Phe Asp Glu Asp Asp Ser Glu Pro Val Leu Lys Gly Val Lys Leu
1265 1270 1275 1280
His Tyr Thr
<210> 4
<211> 1283
<212> PRT
<213> 重组蛋白()
<400> 4
Met Asp Ala Met Lys Arg Gly Leu Cys Cys Val Leu Leu Leu Cys Gly
1 5 10 15
Ala Val Phe Val Ser Ala Arg Gln Cys Val Asn Leu Thr Thr Arg Thr
20 25 30
Gln Leu Pro Pro Ala Tyr Thr Asn Ser Phe Thr Arg Gly Val Tyr Tyr
35 40 45
Pro Asp Lys Val Phe Arg Ser Ser Val Leu His Ser Thr Gln Asp Leu
50 55 60
Phe Leu Pro Phe Phe Ser Asn Val Thr Trp Phe His Ala Ile His Val
65 70 75 80
Ser Gly Thr Asn Gly Thr Lys Arg Phe Asp Asn Pro Val Leu Pro Phe
85 90 95
Asn Asp Gly Val Tyr Phe Ala Ser Thr Glu Lys Ser Asn Ile Ile Arg
100 105 110
Gly Trp Ile Phe Gly Thr Thr Leu Asp Ser Lys Thr Gln Ser Leu Leu
115 120 125
Ile Val Asn Asn Ala Thr Asn Val Val Ile Lys Val Cys Glu Phe Gln
130 135 140
Phe Cys Asn Asp Pro Phe Leu Gly Val Tyr Tyr His Lys Asn Asn Lys
145 150 155 160
Ser Trp Met Glu Ser Glu Phe Arg Val Tyr Ser Ser Ala Asn Asn Cys
165 170 175
Thr Phe Glu Tyr Val Ser Gln Pro Phe Leu Met Asp Leu Glu Gly Lys
180 185 190
Gln Gly Asn Phe Lys Asn Leu Arg Glu Phe Val Phe Lys Asn Ile Asp
195 200 205
Gly Tyr Phe Lys Ile Tyr Ser Lys His Thr Pro Ile Asn Leu Val Arg
210 215 220
Asp Leu Pro Gln Gly Phe Ser Ala Leu Glu Pro Leu Val Asp Leu Pro
225 230 235 240
Ile Gly Ile Asn Ile Thr Arg Phe Gln Thr Leu Leu Ala Leu His Arg
245 250 255
Ser Tyr Leu Thr Pro Gly Asp Ser Ser Ser Gly Trp Thr Ala Gly Ala
260 265 270
Ala Ala Tyr Tyr Val Gly Tyr Leu Gln Pro Arg Thr Phe Leu Leu Lys
275 280 285
Tyr Asn Glu Asn Gly Thr Ile Thr Asp Ala Val Asp Cys Ala Leu Asp
290 295 300
Pro Leu Ser Glu Thr Lys Cys Thr Leu Lys Ser Phe Thr Val Glu Lys
305 310 315 320
Gly Ile Tyr Gln Thr Ser Asn Phe Arg Val Gln Pro Thr Glu Ser Ile
325 330 335
Val Arg Phe Pro Asn Ile Thr Asn Leu Cys Pro Phe Gly Glu Val Phe
340 345 350
Asn Ala Thr Arg Phe Ala Ser Val Tyr Ala Trp Asn Arg Lys Arg Ile
355 360 365
Ser Asn Cys Val Ala Asp Tyr Ser Val Leu Tyr Asn Ser Ala Ser Phe
370 375 380
Ser Thr Phe Lys Cys Tyr Gly Val Ser Pro Thr Lys Leu Asn Asp Leu
385 390 395 400
Cys Phe Thr Asn Val Tyr Ala Asp Ser Phe Val Ile Arg Gly Asp Glu
405 410 415
Val Arg Gln Ile Ala Pro Gly Gln Thr Gly Lys Ile Ala Asp Tyr Asn
420 425 430
Tyr Lys Leu Pro Asp Asp Phe Thr Gly Cys Val Ile Ala Trp Asn Ser
435 440 445
Asn Asn Leu Asp Ser Lys Val Gly Gly Asn Tyr Asn Tyr Leu Tyr Arg
450 455 460
Leu Phe Arg Lys Ser Asn Leu Lys Pro Phe Glu Arg Asp Ile Ser Thr
465 470 475 480
Glu Ile Tyr Gln Ala Gly Ser Thr Pro Cys Asn Gly Val Glu Gly Phe
485 490 495
Asn Cys Tyr Phe Pro Leu Gln Ser Tyr Gly Phe Gln Pro Thr Asn Gly
500 505 510
Val Gly Tyr Gln Pro Tyr Arg Val Val Val Leu Ser Phe Glu Leu Leu
515 520 525
His Ala Pro Ala Thr Val Cys Gly Pro Lys Lys Ser Thr Asn Leu Val
530 535 540
Lys Asn Lys Cys Val Asn Phe Asn Phe Asn Gly Leu Thr Gly Thr Gly
545 550 555 560
Val Leu Thr Glu Ser Asn Lys Lys Phe Leu Pro Phe Gln Gln Phe Gly
565 570 575
Arg Asp Ile Ala Asp Thr Thr Asp Ala Val Arg Asp Pro Gln Thr Leu
580 585 590
Glu Ile Leu Asp Ile Thr Pro Cys Ser Phe Gly Gly Val Ser Val Ile
595 600 605
Thr Pro Gly Thr Asn Thr Ser Asn Gln Val Ala Val Leu Tyr Gln Asp
610 615 620
Val Asn Cys Thr Glu Val Pro Val Ala Ile His Ala Asp Gln Leu Thr
625 630 635 640
Pro Thr Trp Arg Val Tyr Ser Thr Gly Ser Asn Val Phe Gln Thr Arg
645 650 655
Ala Gly Cys Leu Ile Gly Ala Glu His Val Asn Asn Ser Tyr Glu Cys
660 665 670
Asp Ile Pro Ile Gly Ala Gly Ile Cys Ala Ser Tyr Gln Thr Gln Thr
675 680 685
Asn Ser Pro Gly Ser Ala Ser Ser Val Ala Ser Gln Ser Ile Ile Ala
690 695 700
Tyr Thr Met Ser Leu Gly Ala Glu Asn Ser Val Ala Tyr Ser Asn Asn
705 710 715 720
Ser Ile Ala Ile Pro Thr Asn Phe Thr Ile Ser Val Thr Thr Glu Ile
725 730 735
Leu Pro Val Ser Met Thr Lys Thr Ser Val Asp Cys Thr Met Tyr Ile
740 745 750
Cys Gly Asp Ser Thr Glu Cys Ser Asn Leu Leu Leu Gln Tyr Gly Ser
755 760 765
Phe Cys Thr Gln Leu Asn Arg Ala Leu Thr Gly Ile Ala Val Glu Gln
770 775 780
Asp Lys Asn Thr Gln Glu Val Phe Ala Gln Val Lys Gln Ile Tyr Lys
785 790 795 800
Thr Pro Pro Ile Lys Asp Phe Gly Gly Phe Asn Phe Ser Gln Ile Leu
805 810 815
Pro Asp Pro Ser Lys Pro Ser Lys Arg Ser Pro Ile Glu Asp Leu Leu
820 825 830
Phe Asn Lys Val Thr Leu Ala Asp Ala Gly Phe Ile Lys Gln Tyr Gly
835 840 845
Asp Cys Leu Gly Asp Ile Ala Ala Arg Asp Leu Ile Cys Ala Gln Lys
850 855 860
Phe Asn Gly Leu Thr Val Leu Pro Pro Leu Leu Thr Asp Glu Met Ile
865 870 875 880
Ala Gln Tyr Thr Ser Ala Leu Leu Ala Gly Thr Ile Thr Ser Gly Trp
885 890 895
Thr Phe Gly Ala Gly Pro Ala Leu Gln Ile Pro Phe Pro Met Gln Met
900 905 910
Ala Tyr Arg Phe Asn Gly Ile Gly Val Thr Gln Asn Val Leu Tyr Glu
915 920 925
Asn Gln Lys Leu Ile Ala Asn Gln Phe Asn Ser Ala Ile Gly Lys Ile
930 935 940
Gln Asp Ser Leu Ser Ser Thr Pro Ser Ala Leu Gly Lys Leu Gln Asp
945 950 955 960
Val Val Asn Gln Asn Ala Gln Ala Leu Asn Thr Leu Val Lys Gln Leu
965 970 975
Ser Ser Asn Phe Gly Ala Ile Ser Ser Val Leu Asn Asp Ile Leu Ser
980 985 990
Arg Leu Asp Pro Pro Glu Ala Glu Val Gln Ile Asp Arg Leu Ile Thr
995 1000 1005
Gly Arg Leu Gln Ser Leu Gln Thr Tyr Val Thr Gln Gln Leu Ile Arg
1010 1015 1020
Ala Ala Glu Ile Arg Ala Ser Ala Asn Leu Ala Ala Thr Lys Met Ser
1025 1030 1035 1040
Glu Cys Val Leu Gly Gln Ser Lys Arg Val Asp Phe Cys Gly Lys Gly
1045 1050 1055
Tyr His Leu Met Ser Phe Pro Gln Ser Ala Pro His Gly Val Val Phe
1060 1065 1070
Leu His Val Thr Tyr Val Pro Ala Gln Glu Lys Asn Phe Thr Thr Ala
1075 1080 1085
Pro Ala Ile Cys His Asp Gly Lys Ala His Phe Pro Arg Glu Gly Val
1090 1095 1100
Phe Val Ser Asn Gly Thr His Trp Phe Val Thr Gln Arg Asn Phe Tyr
1105 1110 1115 1120
Glu Pro Gln Ile Ile Thr Thr Asp Asn Thr Phe Val Ser Gly Asn Cys
1125 1130 1135
Asp Val Val Ile Gly Ile Val Asn Asn Thr Val Tyr Asp Pro Leu Gln
1140 1145 1150
Pro Glu Leu Asp Ser Phe Lys Glu Glu Leu Asp Lys Tyr Phe Lys Asn
1155 1160 1165
His Thr Ser Pro Asp Val Asp Leu Gly Asp Ile Ser Gly Ile Asn Ala
1170 1175 1180
Ser Val Val Asn Ile Gln Lys Glu Ile Asp Arg Leu Asn Glu Val Ala
1185 1190 1195 1200
Lys Asn Leu Asn Glu Ser Leu Ile Asp Leu Gln Glu Leu Gly Lys Tyr
1205 1210 1215
Glu Gln Tyr Ile Lys Trp Pro Trp Tyr Ile Trp Leu Gly Phe Ile Ala
1220 1225 1230
Gly Leu Ile Ala Ile Val Met Val Thr Ile Met Leu Cys Cys Met Thr
1235 1240 1245
Ser Cys Cys Ser Cys Leu Lys Gly Cys Cys Ser Cys Gly Ser Cys Cys
1250 1255 1260
Lys Phe Asp Glu Asp Asp Ser Glu Pro Val Leu Lys Gly Val Lys Leu
1265 1270 1275 1280
His Tyr Thr
<210> 5
<211> 3852
<212> PRT
<213> 重组核苷酸()
<400> 5
Ala Thr Gly Gly Ala Cys Gly Cys Cys Ala Thr Gly Ala Ala Gly Cys
1 5 10 15
Gly Cys Gly Gly Cys Cys Thr Gly Thr Gly Cys Thr Gly Cys Gly Thr
20 25 30
Gly Cys Thr Gly Cys Thr Gly Cys Thr Gly Thr Gly Cys Gly Gly Cys
35 40 45
Gly Cys Cys Gly Thr Gly Thr Thr Cys Gly Thr Gly Thr Cys Cys Gly
50 55 60
Cys Cys Cys Gly Cys Cys Ala Gly Thr Gly Cys Gly Thr Gly Ala Ala
65 70 75 80
Cys Cys Thr Gly Ala Cys Cys Ala Cys Cys Cys Gly Cys Ala Cys Cys
85 90 95
Cys Ala Gly Cys Thr Gly Cys Cys Cys Cys Cys Cys Gly Cys Cys Thr
100 105 110
Ala Cys Ala Cys Cys Ala Ala Cys Thr Cys Cys Thr Thr Cys Ala Cys
115 120 125
Cys Cys Gly Cys Gly Gly Cys Gly Thr Gly Thr Ala Cys Thr Ala Cys
130 135 140
Cys Cys Cys Gly Ala Cys Ala Ala Gly Gly Thr Gly Thr Thr Cys Cys
145 150 155 160
Gly Cys Thr Cys Cys Thr Cys Cys Gly Thr Gly Cys Thr Gly Cys Ala
165 170 175
Cys Thr Cys Cys Ala Cys Cys Cys Ala Gly Gly Ala Cys Cys Thr Gly
180 185 190
Thr Thr Cys Cys Thr Gly Cys Cys Cys Thr Thr Cys Thr Thr Cys Thr
195 200 205
Cys Cys Ala Ala Cys Gly Thr Gly Ala Cys Cys Thr Gly Gly Thr Thr
210 215 220
Cys Cys Ala Cys Gly Cys Cys Ala Thr Cys Cys Ala Cys Gly Thr Gly
225 230 235 240
Thr Cys Cys Gly Gly Cys Ala Cys Cys Ala Ala Cys Gly Gly Cys Ala
245 250 255
Cys Cys Ala Ala Gly Cys Gly Cys Thr Thr Cys Gly Ala Cys Ala Ala
260 265 270
Cys Cys Cys Cys Gly Thr Gly Cys Thr Gly Cys Cys Cys Thr Thr Cys
275 280 285
Ala Ala Cys Gly Ala Cys Gly Gly Cys Gly Thr Gly Thr Ala Cys Thr
290 295 300
Thr Cys Gly Cys Cys Thr Cys Cys Ala Cys Cys Gly Ala Gly Ala Ala
305 310 315 320
Gly Thr Cys Cys Ala Ala Cys Ala Thr Cys Ala Thr Cys Cys Gly Cys
325 330 335
Gly Gly Cys Thr Gly Gly Ala Thr Cys Thr Thr Cys Gly Gly Cys Ala
340 345 350
Cys Cys Ala Cys Cys Cys Thr Gly Gly Ala Cys Thr Cys Cys Ala Ala
355 360 365
Gly Ala Cys Cys Cys Ala Gly Thr Cys Cys Cys Thr Gly Cys Thr Gly
370 375 380
Ala Thr Cys Gly Thr Gly Ala Ala Cys Ala Ala Cys Gly Cys Cys Ala
385 390 395 400
Cys Cys Ala Ala Cys Gly Thr Gly Gly Thr Gly Ala Thr Cys Ala Ala
405 410 415
Gly Gly Thr Gly Thr Gly Cys Gly Ala Gly Thr Thr Cys Cys Ala Gly
420 425 430
Thr Thr Cys Thr Gly Cys Ala Ala Cys Gly Ala Cys Cys Cys Cys Thr
435 440 445
Thr Cys Cys Thr Gly Gly Gly Cys Gly Thr Gly Thr Ala Cys Thr Ala
450 455 460
Cys Cys Ala Cys Ala Ala Gly Ala Ala Cys Ala Ala Cys Ala Ala Gly
465 470 475 480
Thr Cys Cys Thr Gly Gly Ala Thr Gly Gly Ala Gly Thr Cys Cys Gly
485 490 495
Ala Gly Thr Thr Cys Cys Gly Cys Gly Thr Gly Thr Ala Cys Thr Cys
500 505 510
Cys Thr Cys Cys Gly Cys Cys Ala Ala Cys Ala Ala Cys Thr Gly Cys
515 520 525
Ala Cys Cys Thr Thr Cys Gly Ala Gly Thr Ala Cys Gly Thr Gly Thr
530 535 540
Cys Cys Cys Ala Gly Cys Cys Cys Thr Thr Cys Cys Thr Gly Ala Thr
545 550 555 560
Gly Gly Ala Cys Cys Thr Gly Gly Ala Gly Gly Gly Cys Ala Ala Gly
565 570 575
Cys Ala Gly Gly Gly Cys Ala Ala Cys Thr Thr Cys Ala Ala Gly Ala
580 585 590
Ala Cys Cys Thr Gly Cys Gly Cys Gly Ala Gly Thr Thr Cys Gly Thr
595 600 605
Gly Thr Thr Cys Ala Ala Gly Ala Ala Cys Ala Thr Cys Gly Ala Cys
610 615 620
Gly Gly Cys Thr Ala Cys Thr Thr Cys Ala Ala Gly Ala Thr Cys Thr
625 630 635 640
Ala Cys Thr Cys Cys Ala Ala Gly Cys Ala Cys Ala Cys Cys Cys Cys
645 650 655
Cys Ala Thr Cys Ala Ala Cys Cys Thr Gly Gly Thr Gly Cys Gly Cys
660 665 670
Gly Ala Cys Cys Thr Gly Cys Cys Cys Cys Ala Gly Gly Gly Cys Thr
675 680 685
Thr Cys Thr Cys Cys Gly Cys Cys Cys Thr Gly Gly Ala Gly Cys Cys
690 695 700
Cys Cys Thr Gly Gly Thr Gly Gly Ala Cys Cys Thr Gly Cys Cys Cys
705 710 715 720
Ala Thr Cys Gly Gly Cys Ala Thr Cys Ala Ala Cys Ala Thr Cys Ala
725 730 735
Cys Cys Cys Gly Cys Thr Thr Cys Cys Ala Gly Ala Cys Cys Cys Thr
740 745 750
Gly Cys Thr Gly Gly Cys Cys Cys Thr Gly Cys Ala Cys Cys Gly Cys
755 760 765
Thr Cys Cys Thr Ala Cys Cys Thr Gly Ala Cys Cys Cys Cys Cys Gly
770 775 780
Gly Cys Gly Ala Cys Thr Cys Cys Thr Cys Cys Thr Cys Cys Gly Gly
785 790 795 800
Cys Thr Gly Gly Ala Cys Cys Gly Cys Cys Gly Gly Cys Gly Cys Cys
805 810 815
Gly Cys Cys Gly Cys Cys Thr Ala Cys Thr Ala Cys Gly Thr Gly Gly
820 825 830
Gly Cys Thr Ala Cys Cys Thr Gly Cys Ala Gly Cys Cys Cys Cys Gly
835 840 845
Cys Ala Cys Cys Thr Thr Cys Cys Thr Gly Cys Thr Gly Ala Ala Gly
850 855 860
Thr Ala Cys Ala Ala Cys Gly Ala Gly Ala Ala Cys Gly Gly Cys Ala
865 870 875 880
Cys Cys Ala Thr Cys Ala Cys Cys Gly Ala Cys Gly Cys Cys Gly Thr
885 890 895
Gly Gly Ala Cys Thr Gly Cys Gly Cys Cys Cys Thr Gly Gly Ala Cys
900 905 910
Cys Cys Cys Cys Thr Gly Thr Cys Cys Gly Ala Gly Ala Cys Cys Ala
915 920 925
Ala Gly Thr Gly Cys Ala Cys Cys Cys Thr Gly Ala Ala Gly Thr Cys
930 935 940
Cys Thr Thr Cys Ala Cys Cys Gly Thr Gly Gly Ala Gly Ala Ala Gly
945 950 955 960
Gly Gly Cys Ala Thr Cys Thr Ala Cys Cys Ala Gly Ala Cys Cys Thr
965 970 975
Cys Cys Ala Ala Cys Thr Thr Cys Cys Gly Cys Gly Thr Gly Cys Ala
980 985 990
Gly Cys Cys Cys Ala Cys Cys Gly Ala Gly Thr Cys Cys Ala Thr Cys
995 1000 1005
Gly Thr Gly Cys Gly Cys Thr Thr Cys Cys Cys Cys Ala Ala Cys Ala
1010 1015 1020
Thr Cys Ala Cys Cys Ala Ala Cys Cys Thr Gly Thr Gly Cys Cys Cys
1025 1030 1035 1040
Cys Thr Thr Cys Gly Gly Cys Gly Ala Gly Gly Thr Gly Thr Thr Cys
1045 1050 1055
Ala Ala Cys Gly Cys Cys Ala Cys Cys Cys Gly Cys Thr Thr Cys Gly
1060 1065 1070
Cys Cys Thr Cys Cys Gly Thr Gly Thr Ala Cys Gly Cys Cys Thr Gly
1075 1080 1085
Gly Ala Ala Cys Cys Gly Cys Ala Ala Gly Cys Gly Cys Ala Thr Cys
1090 1095 1100
Thr Cys Cys Ala Ala Cys Thr Gly Cys Gly Thr Gly Gly Cys Cys Gly
1105 1110 1115 1120
Ala Cys Thr Ala Cys Thr Cys Cys Gly Thr Gly Cys Thr Gly Thr Ala
1125 1130 1135
Cys Ala Ala Cys Thr Cys Cys Gly Cys Cys Thr Cys Cys Thr Thr Cys
1140 1145 1150
Thr Cys Cys Ala Cys Cys Thr Thr Cys Ala Ala Gly Thr Gly Cys Thr
1155 1160 1165
Ala Cys Gly Gly Cys Gly Thr Gly Thr Cys Cys Cys Cys Cys Ala Cys
1170 1175 1180
Cys Ala Ala Gly Cys Thr Gly Ala Ala Cys Gly Ala Cys Cys Thr Gly
1185 1190 1195 1200
Thr Gly Cys Thr Thr Cys Ala Cys Cys Ala Ala Cys Gly Thr Gly Thr
1205 1210 1215
Ala Cys Gly Cys Cys Gly Ala Cys Thr Cys Cys Thr Thr Cys Gly Thr
1220 1225 1230
Gly Ala Thr Cys Cys Gly Cys Gly Gly Cys Gly Ala Cys Gly Ala Gly
1235 1240 1245
Gly Thr Gly Cys Gly Cys Cys Ala Gly Ala Thr Cys Gly Cys Cys Cys
1250 1255 1260
Cys Cys Gly Gly Cys Cys Ala Gly Ala Cys Cys Gly Gly Cys Ala Ala
1265 1270 1275 1280
Gly Ala Thr Cys Gly Cys Cys Gly Ala Cys Thr Ala Cys Ala Ala Cys
1285 1290 1295
Thr Ala Cys Ala Ala Gly Cys Thr Gly Cys Cys Cys Gly Ala Cys Gly
1300 1305 1310
Ala Cys Thr Thr Cys Ala Cys Cys Gly Gly Cys Thr Gly Cys Gly Thr
1315 1320 1325
Gly Ala Thr Cys Gly Cys Cys Thr Gly Gly Ala Ala Cys Thr Cys Cys
1330 1335 1340
Ala Ala Cys Ala Ala Cys Cys Thr Gly Gly Ala Cys Thr Cys Cys Ala
1345 1350 1355 1360
Ala Gly Gly Thr Gly Gly Gly Cys Gly Gly Cys Ala Ala Cys Thr Ala
1365 1370 1375
Cys Ala Ala Cys Thr Ala Cys Cys Thr Gly Thr Ala Cys Cys Gly Cys
1380 1385 1390
Cys Thr Gly Thr Thr Cys Cys Gly Cys Ala Ala Gly Thr Cys Cys Ala
1395 1400 1405
Ala Cys Cys Thr Gly Ala Ala Gly Cys Cys Cys Thr Thr Cys Gly Ala
1410 1415 1420
Gly Cys Gly Cys Gly Ala Cys Ala Thr Cys Thr Cys Cys Ala Cys Cys
1425 1430 1435 1440
Gly Ala Gly Ala Thr Cys Thr Ala Cys Cys Ala Gly Gly Cys Cys Gly
1445 1450 1455
Gly Cys Thr Cys Cys Ala Cys Cys Cys Cys Cys Thr Gly Cys Ala Ala
1460 1465 1470
Cys Gly Gly Cys Gly Thr Gly Gly Ala Gly Gly Gly Cys Thr Thr Cys
1475 1480 1485
Ala Ala Cys Thr Gly Cys Thr Ala Cys Thr Thr Cys Cys Cys Cys Cys
1490 1495 1500
Thr Gly Cys Ala Gly Thr Cys Cys Thr Ala Cys Gly Gly Cys Thr Thr
1505 1510 1515 1520
Cys Cys Ala Gly Cys Cys Cys Ala Cys Cys Ala Ala Cys Gly Gly Cys
1525 1530 1535
Gly Thr Gly Gly Gly Cys Thr Ala Cys Cys Ala Gly Cys Cys Cys Thr
1540 1545 1550
Ala Cys Cys Gly Cys Gly Thr Gly Gly Thr Gly Gly Thr Gly Cys Thr
1555 1560 1565
Gly Thr Cys Cys Thr Thr Cys Gly Ala Gly Cys Thr Gly Cys Thr Gly
1570 1575 1580
Cys Ala Cys Gly Cys Cys Cys Cys Cys Gly Cys Cys Ala Cys Cys Gly
1585 1590 1595 1600
Thr Gly Thr Gly Cys Gly Gly Cys Cys Cys Cys Ala Ala Gly Ala Ala
1605 1610 1615
Gly Thr Cys Cys Ala Cys Cys Ala Ala Cys Cys Thr Gly Gly Thr Gly
1620 1625 1630
Ala Ala Gly Ala Ala Cys Ala Ala Gly Thr Gly Cys Gly Thr Gly Ala
1635 1640 1645
Ala Cys Thr Thr Cys Ala Ala Cys Thr Thr Cys Ala Ala Cys Gly Gly
1650 1655 1660
Cys Cys Thr Gly Ala Cys Cys Gly Gly Cys Ala Cys Cys Gly Gly Cys
1665 1670 1675 1680
Gly Thr Gly Cys Thr Gly Ala Cys Cys Gly Ala Gly Thr Cys Cys Ala
1685 1690 1695
Ala Cys Ala Ala Gly Ala Ala Gly Thr Thr Cys Cys Thr Gly Cys Cys
1700 1705 1710
Cys Thr Thr Cys Cys Ala Gly Cys Ala Gly Thr Thr Cys Gly Gly Cys
1715 1720 1725
Cys Gly Cys Gly Ala Cys Ala Thr Cys Gly Cys Cys Gly Ala Cys Ala
1730 1735 1740
Cys Cys Ala Cys Cys Gly Ala Cys Gly Cys Cys Gly Thr Gly Cys Gly
1745 1750 1755 1760
Cys Gly Ala Cys Cys Cys Cys Cys Ala Gly Ala Cys Cys Cys Thr Gly
1765 1770 1775
Gly Ala Gly Ala Thr Cys Cys Thr Gly Gly Ala Cys Ala Thr Cys Ala
1780 1785 1790
Cys Cys Cys Cys Cys Thr Gly Cys Thr Cys Cys Thr Thr Cys Gly Gly
1795 1800 1805
Cys Gly Gly Cys Gly Thr Gly Thr Cys Cys Gly Thr Gly Ala Thr Cys
1810 1815 1820
Ala Cys Cys Cys Cys Cys Gly Gly Cys Ala Cys Cys Ala Ala Cys Ala
1825 1830 1835 1840
Cys Cys Thr Cys Cys Ala Ala Cys Cys Ala Gly Gly Thr Gly Gly Cys
1845 1850 1855
Cys Gly Thr Gly Cys Thr Gly Thr Ala Cys Cys Ala Gly Gly Ala Cys
1860 1865 1870
Gly Thr Gly Ala Ala Cys Thr Gly Cys Ala Cys Cys Gly Ala Gly Gly
1875 1880 1885
Thr Gly Cys Cys Cys Gly Thr Gly Gly Cys Cys Ala Thr Cys Cys Ala
1890 1895 1900
Cys Gly Cys Cys Gly Ala Cys Cys Ala Gly Cys Thr Gly Ala Cys Cys
1905 1910 1915 1920
Cys Cys Cys Ala Cys Cys Thr Gly Gly Cys Gly Cys Gly Thr Gly Thr
1925 1930 1935
Ala Cys Thr Cys Cys Ala Cys Cys Gly Gly Cys Thr Cys Cys Ala Ala
1940 1945 1950
Cys Gly Thr Gly Thr Thr Cys Cys Ala Gly Ala Cys Cys Cys Gly Cys
1955 1960 1965
Gly Cys Cys Gly Gly Cys Thr Gly Cys Cys Thr Gly Ala Thr Cys Gly
1970 1975 1980
Gly Cys Gly Cys Cys Gly Ala Gly Cys Ala Cys Gly Thr Gly Ala Ala
1985 1990 1995 2000
Cys Ala Ala Cys Thr Cys Cys Thr Ala Cys Gly Ala Gly Thr Gly Cys
2005 2010 2015
Gly Ala Cys Ala Thr Cys Cys Cys Cys Ala Thr Cys Gly Gly Cys Gly
2020 2025 2030
Cys Cys Gly Gly Cys Ala Thr Cys Thr Gly Cys Gly Cys Cys Thr Cys
2035 2040 2045
Cys Thr Ala Cys Cys Ala Gly Ala Cys Cys Cys Ala Gly Ala Cys Cys
2050 2055 2060
Ala Ala Cys Thr Cys Cys Cys Cys Cys Cys Gly Cys Cys Gly Cys Gly
2065 2070 2075 2080
Cys Cys Cys Gly Cys Thr Cys Cys Gly Thr Gly Gly Cys Cys Thr Cys
2085 2090 2095
Cys Cys Ala Gly Thr Cys Cys Ala Thr Cys Ala Thr Cys Gly Cys Cys
2100 2105 2110
Thr Ala Cys Ala Cys Cys Ala Thr Gly Thr Cys Cys Cys Thr Gly Gly
2115 2120 2125
Gly Cys Gly Cys Cys Gly Ala Gly Ala Ala Cys Thr Cys Cys Gly Thr
2130 2135 2140
Gly Gly Cys Cys Thr Ala Cys Thr Cys Cys Ala Ala Cys Ala Ala Cys
2145 2150 2155 2160
Thr Cys Cys Ala Thr Cys Gly Cys Cys Ala Thr Cys Cys Cys Cys Ala
2165 2170 2175
Cys Cys Ala Ala Cys Thr Thr Cys Ala Cys Cys Ala Thr Cys Thr Cys
2180 2185 2190
Cys Gly Thr Gly Ala Cys Cys Ala Cys Cys Gly Ala Gly Ala Thr Cys
2195 2200 2205
Cys Thr Gly Cys Cys Cys Gly Thr Gly Thr Cys Cys Ala Thr Gly Ala
2210 2215 2220
Cys Cys Ala Ala Gly Ala Cys Cys Thr Cys Cys Gly Thr Gly Gly Ala
2225 2230 2235 2240
Cys Thr Gly Cys Ala Cys Cys Ala Thr Gly Thr Ala Cys Ala Thr Cys
2245 2250 2255
Thr Gly Cys Gly Gly Cys Gly Ala Cys Thr Cys Cys Ala Cys Cys Gly
2260 2265 2270
Ala Gly Thr Gly Cys Thr Cys Cys Ala Ala Cys Cys Thr Gly Cys Thr
2275 2280 2285
Gly Cys Thr Gly Cys Ala Gly Thr Ala Cys Gly Gly Cys Thr Cys Cys
2290 2295 2300
Thr Thr Cys Thr Gly Cys Ala Cys Cys Cys Ala Gly Cys Thr Gly Ala
2305 2310 2315 2320
Ala Cys Cys Gly Cys Gly Cys Cys Cys Thr Gly Ala Cys Cys Gly Gly
2325 2330 2335
Cys Ala Thr Cys Gly Cys Cys Gly Thr Gly Gly Ala Gly Cys Ala Gly
2340 2345 2350
Gly Ala Cys Ala Ala Gly Ala Ala Cys Ala Cys Cys Cys Ala Gly Gly
2355 2360 2365
Ala Gly Gly Thr Gly Thr Thr Cys Gly Cys Cys Cys Ala Gly Gly Thr
2370 2375 2380
Gly Ala Ala Gly Cys Ala Gly Ala Thr Cys Thr Ala Cys Ala Ala Gly
2385 2390 2395 2400
Ala Cys Cys Cys Cys Cys Cys Cys Cys Ala Thr Cys Ala Ala Gly Gly
2405 2410 2415
Ala Cys Thr Thr Cys Gly Gly Cys Gly Gly Cys Thr Thr Cys Ala Ala
2420 2425 2430
Cys Thr Thr Cys Thr Cys Cys Cys Ala Gly Ala Thr Cys Cys Thr Gly
2435 2440 2445
Cys Cys Cys Gly Ala Cys Cys Cys Cys Thr Cys Cys Ala Ala Gly Cys
2450 2455 2460
Cys Cys Thr Cys Cys Ala Ala Gly Cys Gly Cys Thr Cys Cys Thr Thr
2465 2470 2475 2480
Cys Ala Thr Cys Gly Ala Gly Gly Ala Cys Cys Thr Gly Cys Thr Gly
2485 2490 2495
Thr Thr Cys Ala Ala Cys Ala Ala Gly Gly Thr Gly Ala Cys Cys Cys
2500 2505 2510
Thr Gly Gly Cys Cys Gly Ala Cys Gly Cys Cys Gly Gly Cys Thr Thr
2515 2520 2525
Cys Ala Thr Cys Ala Ala Gly Cys Ala Gly Thr Ala Cys Gly Gly Cys
2530 2535 2540
Gly Ala Cys Thr Gly Cys Cys Thr Gly Gly Gly Cys Gly Ala Cys Ala
2545 2550 2555 2560
Thr Cys Gly Cys Cys Gly Cys Cys Cys Gly Cys Gly Ala Cys Cys Thr
2565 2570 2575
Gly Ala Thr Cys Thr Gly Cys Gly Cys Cys Cys Ala Gly Ala Ala Gly
2580 2585 2590
Thr Thr Cys Ala Ala Cys Gly Gly Cys Cys Thr Gly Ala Cys Cys Gly
2595 2600 2605
Thr Gly Cys Thr Gly Cys Cys Cys Cys Cys Cys Cys Thr Gly Cys Thr
2610 2615 2620
Gly Ala Cys Cys Gly Ala Cys Gly Ala Gly Ala Thr Gly Ala Thr Cys
2625 2630 2635 2640
Gly Cys Cys Cys Ala Gly Thr Ala Cys Ala Cys Cys Thr Cys Cys Gly
2645 2650 2655
Cys Cys Cys Thr Gly Cys Thr Gly Gly Cys Cys Gly Gly Cys Ala Cys
2660 2665 2670
Cys Ala Thr Cys Ala Cys Cys Thr Cys Cys Gly Gly Cys Thr Gly Gly
2675 2680 2685
Ala Cys Cys Thr Thr Cys Gly Gly Cys Gly Cys Cys Gly Gly Cys Gly
2690 2695 2700
Cys Cys Gly Cys Cys Cys Thr Gly Cys Ala Gly Ala Thr Cys Cys Cys
2705 2710 2715 2720
Cys Thr Thr Cys Gly Cys Cys Ala Thr Gly Cys Ala Gly Ala Thr Gly
2725 2730 2735
Gly Cys Cys Thr Ala Cys Cys Gly Cys Thr Thr Cys Ala Ala Cys Gly
2740 2745 2750
Gly Cys Ala Thr Cys Gly Gly Cys Gly Thr Gly Ala Cys Cys Cys Ala
2755 2760 2765
Gly Ala Ala Cys Gly Thr Gly Cys Thr Gly Thr Ala Cys Gly Ala Gly
2770 2775 2780
Ala Ala Cys Cys Ala Gly Ala Ala Gly Cys Thr Gly Ala Thr Cys Gly
2785 2790 2795 2800
Cys Cys Ala Ala Cys Cys Ala Gly Thr Thr Cys Ala Ala Cys Thr Cys
2805 2810 2815
Cys Gly Cys Cys Ala Thr Cys Gly Gly Cys Ala Ala Gly Ala Thr Cys
2820 2825 2830
Cys Ala Gly Gly Ala Cys Thr Cys Cys Cys Thr Gly Thr Cys Cys Thr
2835 2840 2845
Cys Cys Ala Cys Cys Gly Cys Cys Thr Cys Cys Gly Cys Cys Cys Thr
2850 2855 2860
Gly Gly Gly Cys Ala Ala Gly Cys Thr Gly Cys Ala Gly Gly Ala Cys
2865 2870 2875 2880
Gly Thr Gly Gly Thr Gly Ala Ala Cys Cys Ala Gly Ala Ala Cys Gly
2885 2890 2895
Cys Cys Cys Ala Gly Gly Cys Cys Cys Thr Gly Ala Ala Cys Ala Cys
2900 2905 2910
Cys Cys Thr Gly Gly Thr Gly Ala Ala Gly Cys Ala Gly Cys Thr Gly
2915 2920 2925
Thr Cys Cys Thr Cys Cys Ala Ala Cys Thr Thr Cys Gly Gly Cys Gly
2930 2935 2940
Cys Cys Ala Thr Cys Thr Cys Cys Thr Cys Cys Gly Thr Gly Cys Thr
2945 2950 2955 2960
Gly Ala Ala Cys Gly Ala Cys Ala Thr Cys Cys Thr Gly Thr Cys Cys
2965 2970 2975
Cys Gly Cys Cys Thr Gly Gly Ala Cys Ala Ala Gly Gly Thr Gly Gly
2980 2985 2990
Ala Gly Gly Cys Cys Gly Ala Gly Gly Thr Gly Cys Ala Gly Ala Thr
2995 3000 3005
Cys Gly Ala Cys Cys Gly Cys Cys Thr Gly Ala Thr Cys Ala Cys Cys
3010 3015 3020
Gly Gly Cys Cys Gly Cys Cys Thr Gly Cys Ala Gly Thr Cys Cys Cys
3025 3030 3035 3040
Thr Gly Cys Ala Gly Ala Cys Cys Thr Ala Cys Gly Thr Gly Ala Cys
3045 3050 3055
Cys Cys Ala Gly Cys Ala Gly Cys Thr Gly Ala Thr Cys Cys Gly Cys
3060 3065 3070
Gly Cys Cys Gly Cys Cys Gly Ala Gly Ala Thr Cys Cys Gly Cys Gly
3075 3080 3085
Cys Cys Thr Cys Cys Gly Cys Cys Ala Ala Cys Cys Thr Gly Gly Cys
3090 3095 3100
Cys Gly Cys Cys Ala Cys Cys Ala Ala Gly Ala Thr Gly Thr Cys Cys
3105 3110 3115 3120
Gly Ala Gly Thr Gly Cys Gly Thr Gly Cys Thr Gly Gly Gly Cys Cys
3125 3130 3135
Ala Gly Thr Cys Cys Ala Ala Gly Cys Gly Cys Gly Thr Gly Gly Ala
3140 3145 3150
Cys Thr Thr Cys Thr Gly Cys Gly Gly Cys Ala Ala Gly Gly Gly Cys
3155 3160 3165
Thr Ala Cys Cys Ala Cys Cys Thr Gly Ala Thr Gly Thr Cys Cys Thr
3170 3175 3180
Thr Cys Cys Cys Cys Cys Ala Gly Thr Cys Cys Gly Cys Cys Cys Cys
3185 3190 3195 3200
Cys Cys Ala Cys Gly Gly Cys Gly Thr Gly Gly Thr Gly Thr Thr Cys
3205 3210 3215
Cys Thr Gly Cys Ala Cys Gly Thr Gly Ala Cys Cys Thr Ala Cys Gly
3220 3225 3230
Thr Gly Cys Cys Cys Gly Cys Cys Cys Ala Gly Gly Ala Gly Ala Ala
3235 3240 3245
Gly Ala Ala Cys Thr Thr Cys Ala Cys Cys Ala Cys Cys Gly Cys Cys
3250 3255 3260
Cys Cys Cys Gly Cys Cys Ala Thr Cys Thr Gly Cys Cys Ala Cys Gly
3265 3270 3275 3280
Ala Cys Gly Gly Cys Ala Ala Gly Gly Cys Cys Cys Ala Cys Thr Thr
3285 3290 3295
Cys Cys Cys Cys Cys Gly Cys Gly Ala Gly Gly Gly Cys Gly Thr Gly
3300 3305 3310
Thr Thr Cys Gly Thr Gly Thr Cys Cys Ala Ala Cys Gly Gly Cys Ala
3315 3320 3325
Cys Cys Cys Ala Cys Thr Gly Gly Thr Thr Cys Gly Thr Gly Ala Cys
3330 3335 3340
Cys Cys Ala Gly Cys Gly Cys Ala Ala Cys Thr Thr Cys Thr Ala Cys
3345 3350 3355 3360
Gly Ala Gly Cys Cys Cys Cys Ala Gly Ala Thr Cys Ala Thr Cys Ala
3365 3370 3375
Cys Cys Ala Cys Cys Gly Ala Cys Ala Ala Cys Ala Cys Cys Thr Thr
3380 3385 3390
Cys Gly Thr Gly Thr Cys Cys Gly Gly Cys Ala Ala Cys Thr Gly Cys
3395 3400 3405
Gly Ala Cys Gly Thr Gly Gly Thr Gly Ala Thr Cys Gly Gly Cys Ala
3410 3415 3420
Thr Cys Gly Thr Gly Ala Ala Cys Ala Ala Cys Ala Cys Cys Gly Thr
3425 3430 3435 3440
Gly Thr Ala Cys Gly Ala Cys Cys Cys Cys Cys Thr Gly Cys Ala Gly
3445 3450 3455
Cys Cys Cys Gly Ala Gly Cys Thr Gly Gly Ala Cys Thr Cys Cys Thr
3460 3465 3470
Thr Cys Ala Ala Gly Gly Ala Gly Gly Ala Gly Cys Thr Gly Gly Ala
3475 3480 3485
Cys Ala Ala Gly Thr Ala Cys Thr Thr Cys Ala Ala Gly Ala Ala Cys
3490 3495 3500
Cys Ala Cys Ala Cys Cys Thr Cys Cys Cys Cys Cys Gly Ala Cys Gly
3505 3510 3515 3520
Thr Gly Gly Ala Cys Cys Thr Gly Gly Gly Cys Gly Ala Cys Ala Thr
3525 3530 3535
Cys Thr Cys Cys Gly Gly Cys Ala Thr Cys Ala Ala Cys Gly Cys Cys
3540 3545 3550
Thr Cys Cys Gly Thr Gly Gly Thr Gly Ala Ala Cys Ala Thr Cys Cys
3555 3560 3565
Ala Gly Ala Ala Gly Gly Ala Gly Ala Thr Cys Gly Ala Cys Cys Gly
3570 3575 3580
Cys Cys Thr Gly Ala Ala Cys Gly Ala Gly Gly Thr Gly Gly Cys Cys
3585 3590 3595 3600
Ala Ala Gly Ala Ala Cys Cys Thr Gly Ala Ala Cys Gly Ala Gly Thr
3605 3610 3615
Cys Cys Cys Thr Gly Ala Thr Cys Gly Ala Cys Cys Thr Gly Cys Ala
3620 3625 3630
Gly Gly Ala Gly Cys Thr Gly Gly Gly Cys Ala Ala Gly Thr Ala Cys
3635 3640 3645
Gly Ala Gly Cys Ala Gly Thr Ala Cys Ala Thr Cys Ala Ala Gly Thr
3650 3655 3660
Gly Gly Cys Cys Cys Thr Gly Gly Thr Ala Cys Ala Thr Cys Thr Gly
3665 3670 3675 3680
Gly Cys Thr Gly Gly Gly Cys Thr Thr Cys Ala Thr Cys Gly Cys Cys
3685 3690 3695
Gly Gly Cys Cys Thr Gly Ala Thr Cys Gly Cys Cys Ala Thr Cys Gly
3700 3705 3710
Thr Gly Ala Thr Gly Gly Thr Gly Ala Cys Cys Ala Thr Cys Ala Thr
3715 3720 3725
Gly Cys Thr Gly Thr Gly Cys Thr Gly Cys Ala Thr Gly Ala Cys Cys
3730 3735 3740
Thr Cys Cys Thr Gly Cys Thr Gly Cys Thr Cys Cys Thr Gly Cys Cys
3745 3750 3755 3760
Thr Gly Ala Ala Gly Gly Gly Cys Thr Gly Cys Thr Gly Cys Thr Cys
3765 3770 3775
Cys Thr Gly Cys Gly Gly Cys Thr Cys Cys Thr Gly Cys Thr Gly Cys
3780 3785 3790
Ala Ala Gly Thr Thr Cys Gly Ala Cys Gly Ala Gly Gly Ala Cys Gly
3795 3800 3805
Ala Cys Thr Cys Cys Gly Ala Gly Cys Cys Cys Gly Thr Gly Cys Thr
3810 3815 3820
Gly Ala Ala Gly Gly Gly Cys Gly Thr Gly Ala Ala Gly Cys Thr Gly
3825 3830 3835 3840
Cys Ala Cys Thr Ala Cys Ala Cys Cys Thr Ala Ala
3845 3850
<210> 6
<211> 3840
<212> PRT
<213> 重组核苷酸()
<400> 6
Ala Thr Gly Gly Ala Cys Gly Cys Cys Ala Thr Gly Ala Ala Gly Cys
1 5 10 15
Gly Cys Gly Gly Cys Cys Thr Gly Thr Gly Cys Thr Gly Cys Gly Thr
20 25 30
Gly Cys Thr Gly Cys Thr Gly Cys Thr Gly Thr Gly Cys Gly Gly Cys
35 40 45
Gly Cys Cys Gly Thr Gly Thr Thr Cys Gly Thr Gly Thr Cys Cys Gly
50 55 60
Cys Cys Cys Gly Cys Cys Ala Gly Thr Gly Cys Gly Thr Gly Ala Ala
65 70 75 80
Cys Cys Thr Gly Ala Cys Cys Ala Cys Cys Cys Gly Cys Ala Cys Cys
85 90 95
Cys Ala Gly Cys Thr Gly Cys Cys Cys Cys Cys Cys Gly Cys Cys Thr
100 105 110
Ala Cys Ala Cys Cys Ala Ala Cys Thr Cys Cys Thr Thr Cys Ala Cys
115 120 125
Cys Cys Gly Cys Gly Gly Cys Gly Thr Gly Thr Ala Cys Thr Ala Cys
130 135 140
Cys Cys Cys Gly Ala Cys Ala Ala Gly Gly Thr Gly Thr Thr Cys Cys
145 150 155 160
Gly Cys Thr Cys Cys Thr Cys Cys Gly Thr Gly Cys Thr Gly Cys Ala
165 170 175
Cys Thr Cys Cys Ala Cys Cys Cys Ala Gly Gly Ala Cys Cys Thr Gly
180 185 190
Thr Thr Cys Cys Thr Gly Cys Cys Cys Thr Thr Cys Thr Thr Cys Thr
195 200 205
Cys Cys Ala Ala Cys Gly Thr Gly Ala Cys Cys Thr Gly Gly Thr Thr
210 215 220
Cys Cys Ala Cys Gly Cys Cys Ala Thr Cys Cys Ala Cys Gly Thr Gly
225 230 235 240
Thr Cys Cys Gly Gly Cys Ala Cys Cys Ala Ala Cys Gly Gly Cys Ala
245 250 255
Cys Cys Ala Ala Gly Cys Gly Cys Thr Thr Cys Gly Ala Cys Ala Ala
260 265 270
Cys Cys Cys Cys Gly Thr Gly Cys Thr Gly Cys Cys Cys Thr Thr Cys
275 280 285
Ala Ala Cys Gly Ala Cys Gly Gly Cys Gly Thr Gly Thr Ala Cys Thr
290 295 300
Thr Cys Gly Cys Cys Thr Cys Cys Ala Cys Cys Gly Ala Gly Ala Ala
305 310 315 320
Gly Thr Cys Cys Ala Ala Cys Ala Thr Cys Ala Thr Cys Cys Gly Cys
325 330 335
Gly Gly Cys Thr Gly Gly Ala Thr Cys Thr Thr Cys Gly Gly Cys Ala
340 345 350
Cys Cys Ala Cys Cys Cys Thr Gly Gly Ala Cys Thr Cys Cys Ala Ala
355 360 365
Gly Ala Cys Cys Cys Ala Gly Thr Cys Cys Cys Thr Gly Cys Thr Gly
370 375 380
Ala Thr Cys Gly Thr Gly Ala Ala Cys Ala Ala Cys Gly Cys Cys Ala
385 390 395 400
Cys Cys Ala Ala Cys Gly Thr Gly Gly Thr Gly Ala Thr Cys Ala Ala
405 410 415
Gly Gly Thr Gly Thr Gly Cys Gly Ala Gly Thr Thr Cys Cys Ala Gly
420 425 430
Thr Thr Cys Thr Gly Cys Ala Ala Cys Gly Ala Cys Cys Cys Cys Thr
435 440 445
Thr Cys Cys Thr Gly Gly Gly Cys Gly Thr Gly Thr Ala Cys Thr Ala
450 455 460
Cys Cys Ala Cys Ala Ala Gly Ala Ala Cys Ala Ala Cys Ala Ala Gly
465 470 475 480
Thr Cys Cys Thr Gly Gly Ala Thr Gly Gly Ala Gly Thr Cys Cys Gly
485 490 495
Ala Gly Thr Thr Cys Cys Gly Cys Gly Thr Gly Thr Ala Cys Thr Cys
500 505 510
Cys Thr Cys Cys Gly Cys Cys Ala Ala Cys Ala Ala Cys Thr Gly Cys
515 520 525
Ala Cys Cys Thr Thr Cys Gly Ala Gly Thr Ala Cys Gly Thr Gly Thr
530 535 540
Cys Cys Cys Ala Gly Cys Cys Cys Thr Thr Cys Cys Thr Gly Ala Thr
545 550 555 560
Gly Gly Ala Cys Cys Thr Gly Gly Ala Gly Gly Gly Cys Ala Ala Gly
565 570 575
Cys Ala Gly Gly Gly Cys Ala Ala Cys Thr Thr Cys Ala Ala Gly Ala
580 585 590
Ala Cys Cys Thr Gly Cys Gly Cys Gly Ala Gly Thr Thr Cys Gly Thr
595 600 605
Gly Thr Thr Cys Ala Ala Gly Ala Ala Cys Ala Thr Cys Gly Ala Cys
610 615 620
Gly Gly Cys Thr Ala Cys Thr Thr Cys Ala Ala Gly Ala Thr Cys Thr
625 630 635 640
Ala Cys Thr Cys Cys Ala Ala Gly Cys Ala Cys Ala Cys Cys Cys Cys
645 650 655
Cys Ala Thr Cys Ala Ala Cys Cys Thr Gly Gly Thr Gly Cys Gly Cys
660 665 670
Gly Ala Cys Cys Thr Gly Cys Cys Cys Cys Ala Gly Gly Gly Cys Thr
675 680 685
Thr Cys Thr Cys Cys Gly Cys Cys Cys Thr Gly Gly Ala Gly Cys Cys
690 695 700
Cys Cys Thr Gly Gly Thr Gly Gly Ala Cys Cys Thr Gly Cys Cys Cys
705 710 715 720
Ala Thr Cys Gly Gly Cys Ala Thr Cys Ala Ala Cys Ala Thr Cys Ala
725 730 735
Cys Cys Cys Gly Cys Thr Thr Cys Cys Ala Gly Ala Cys Cys Cys Thr
740 745 750
Gly Cys Thr Gly Gly Cys Cys Cys Thr Gly Cys Ala Cys Cys Gly Cys
755 760 765
Thr Cys Cys Thr Ala Cys Cys Thr Gly Ala Cys Cys Cys Cys Cys Gly
770 775 780
Gly Cys Gly Ala Cys Thr Cys Cys Thr Cys Cys Thr Cys Cys Gly Gly
785 790 795 800
Cys Thr Gly Gly Ala Cys Cys Gly Cys Cys Gly Gly Cys Gly Cys Cys
805 810 815
Gly Cys Cys Gly Cys Cys Thr Ala Cys Thr Ala Cys Gly Thr Gly Gly
820 825 830
Gly Cys Thr Ala Cys Cys Thr Gly Cys Ala Gly Cys Cys Cys Cys Gly
835 840 845
Cys Ala Cys Cys Thr Thr Cys Cys Thr Gly Cys Thr Gly Ala Ala Gly
850 855 860
Thr Ala Cys Ala Ala Cys Gly Ala Gly Ala Ala Cys Gly Gly Cys Ala
865 870 875 880
Cys Cys Ala Thr Cys Ala Cys Cys Gly Ala Cys Gly Cys Cys Gly Thr
885 890 895
Gly Gly Ala Cys Thr Gly Cys Gly Cys Cys Cys Thr Gly Gly Ala Cys
900 905 910
Cys Cys Cys Cys Thr Gly Thr Cys Cys Gly Ala Gly Ala Cys Cys Ala
915 920 925
Ala Gly Thr Gly Cys Ala Cys Cys Cys Thr Gly Ala Ala Gly Thr Cys
930 935 940
Cys Thr Thr Cys Ala Cys Cys Gly Thr Gly Gly Ala Gly Ala Ala Gly
945 950 955 960
Gly Gly Cys Ala Thr Cys Thr Ala Cys Cys Ala Gly Ala Cys Cys Thr
965 970 975
Cys Cys Ala Ala Cys Thr Thr Cys Cys Gly Cys Gly Thr Gly Cys Ala
980 985 990
Gly Cys Cys Cys Ala Cys Cys Gly Ala Gly Thr Cys Cys Ala Thr Cys
995 1000 1005
Gly Thr Gly Cys Gly Cys Thr Thr Cys Cys Cys Cys Ala Ala Cys Ala
1010 1015 1020
Thr Cys Ala Cys Cys Ala Ala Cys Cys Thr Gly Thr Gly Cys Cys Cys
1025 1030 1035 1040
Cys Thr Thr Cys Gly Gly Cys Gly Ala Gly Gly Thr Gly Thr Thr Cys
1045 1050 1055
Ala Ala Cys Gly Cys Cys Ala Cys Cys Cys Gly Cys Thr Thr Cys Gly
1060 1065 1070
Cys Cys Thr Cys Cys Gly Thr Gly Thr Ala Cys Gly Cys Cys Thr Gly
1075 1080 1085
Gly Ala Ala Cys Cys Gly Cys Ala Ala Gly Cys Gly Cys Ala Thr Cys
1090 1095 1100
Thr Cys Cys Ala Ala Cys Thr Gly Cys Gly Thr Gly Gly Cys Cys Gly
1105 1110 1115 1120
Ala Cys Thr Ala Cys Thr Cys Cys Gly Thr Gly Cys Thr Gly Thr Ala
1125 1130 1135
Cys Ala Ala Cys Thr Cys Cys Gly Cys Cys Thr Cys Cys Thr Thr Cys
1140 1145 1150
Thr Cys Cys Ala Cys Cys Thr Thr Cys Ala Ala Gly Thr Gly Cys Thr
1155 1160 1165
Ala Cys Gly Gly Cys Gly Thr Gly Thr Cys Cys Cys Cys Cys Ala Cys
1170 1175 1180
Cys Ala Ala Gly Cys Thr Gly Ala Ala Cys Gly Ala Cys Cys Thr Gly
1185 1190 1195 1200
Thr Gly Cys Thr Thr Cys Ala Cys Cys Ala Ala Cys Gly Thr Gly Thr
1205 1210 1215
Ala Cys Gly Cys Cys Gly Ala Cys Thr Cys Cys Thr Thr Cys Gly Thr
1220 1225 1230
Gly Ala Thr Cys Cys Gly Cys Gly Gly Cys Gly Ala Cys Gly Ala Gly
1235 1240 1245
Gly Thr Gly Cys Gly Cys Cys Ala Gly Ala Thr Cys Gly Cys Cys Cys
1250 1255 1260
Cys Cys Gly Gly Cys Cys Ala Gly Ala Cys Cys Gly Gly Cys Ala Ala
1265 1270 1275 1280
Gly Ala Thr Cys Gly Cys Cys Gly Ala Cys Thr Ala Cys Ala Ala Cys
1285 1290 1295
Thr Ala Cys Ala Ala Gly Cys Thr Gly Cys Cys Cys Gly Ala Cys Gly
1300 1305 1310
Ala Cys Thr Thr Cys Ala Cys Cys Gly Gly Cys Thr Gly Cys Gly Thr
1315 1320 1325
Gly Ala Thr Cys Gly Cys Cys Thr Gly Gly Ala Ala Cys Thr Cys Cys
1330 1335 1340
Ala Ala Cys Ala Ala Cys Cys Thr Gly Gly Ala Cys Thr Cys Cys Ala
1345 1350 1355 1360
Ala Gly Gly Thr Gly Gly Gly Cys Gly Gly Cys Ala Ala Cys Thr Ala
1365 1370 1375
Cys Ala Ala Cys Thr Ala Cys Cys Thr Gly Thr Ala Cys Cys Gly Cys
1380 1385 1390
Cys Thr Gly Thr Thr Cys Cys Gly Cys Ala Ala Gly Thr Cys Cys Ala
1395 1400 1405
Ala Cys Cys Thr Gly Ala Ala Gly Cys Cys Cys Thr Thr Cys Gly Ala
1410 1415 1420
Gly Cys Gly Cys Gly Ala Cys Ala Thr Cys Thr Cys Cys Ala Cys Cys
1425 1430 1435 1440
Gly Ala Gly Ala Thr Cys Thr Ala Cys Cys Ala Gly Gly Cys Cys Gly
1445 1450 1455
Gly Cys Thr Cys Cys Ala Cys Cys Cys Cys Cys Thr Gly Cys Ala Ala
1460 1465 1470
Cys Gly Gly Cys Gly Thr Gly Gly Ala Gly Gly Gly Cys Thr Thr Cys
1475 1480 1485
Ala Ala Cys Thr Gly Cys Thr Ala Cys Thr Thr Cys Cys Cys Cys Cys
1490 1495 1500
Thr Gly Cys Ala Gly Thr Cys Cys Thr Ala Cys Gly Gly Cys Thr Thr
1505 1510 1515 1520
Cys Cys Ala Gly Cys Cys Cys Ala Cys Cys Ala Ala Cys Gly Gly Cys
1525 1530 1535
Gly Thr Gly Gly Gly Cys Thr Ala Cys Cys Ala Gly Cys Cys Cys Thr
1540 1545 1550
Ala Cys Cys Gly Cys Gly Thr Gly Gly Thr Gly Gly Thr Gly Cys Thr
1555 1560 1565
Gly Thr Cys Cys Thr Thr Cys Gly Ala Gly Cys Thr Gly Cys Thr Gly
1570 1575 1580
Cys Ala Cys Gly Cys Cys Cys Cys Cys Gly Cys Cys Ala Cys Cys Gly
1585 1590 1595 1600
Thr Gly Thr Gly Cys Gly Gly Cys Cys Cys Cys Ala Ala Gly Ala Ala
1605 1610 1615
Gly Thr Cys Cys Ala Cys Cys Ala Ala Cys Cys Thr Gly Gly Thr Gly
1620 1625 1630
Ala Ala Gly Ala Ala Cys Ala Ala Gly Thr Gly Cys Gly Thr Gly Ala
1635 1640 1645
Ala Cys Thr Thr Cys Ala Ala Cys Thr Thr Cys Ala Ala Cys Gly Gly
1650 1655 1660
Cys Cys Thr Gly Ala Cys Cys Gly Gly Cys Ala Cys Cys Gly Gly Cys
1665 1670 1675 1680
Gly Thr Gly Cys Thr Gly Ala Cys Cys Gly Ala Gly Thr Cys Cys Ala
1685 1690 1695
Ala Cys Ala Ala Gly Ala Ala Gly Thr Thr Cys Cys Thr Gly Cys Cys
1700 1705 1710
Cys Thr Thr Cys Cys Ala Gly Cys Ala Gly Thr Thr Cys Gly Gly Cys
1715 1720 1725
Cys Gly Cys Gly Ala Cys Ala Thr Cys Gly Cys Cys Gly Ala Cys Ala
1730 1735 1740
Cys Cys Ala Cys Cys Gly Ala Cys Gly Cys Cys Gly Thr Gly Cys Gly
1745 1750 1755 1760
Cys Gly Ala Cys Cys Cys Cys Cys Ala Gly Ala Cys Cys Cys Thr Gly
1765 1770 1775
Gly Ala Gly Ala Thr Cys Cys Thr Gly Gly Ala Cys Ala Thr Cys Ala
1780 1785 1790
Cys Cys Cys Cys Cys Thr Gly Cys Thr Cys Cys Thr Thr Cys Gly Gly
1795 1800 1805
Cys Gly Gly Cys Gly Thr Gly Thr Cys Cys Gly Thr Gly Ala Thr Cys
1810 1815 1820
Ala Cys Cys Cys Cys Cys Gly Gly Cys Ala Cys Cys Ala Ala Cys Ala
1825 1830 1835 1840
Cys Cys Thr Cys Cys Ala Ala Cys Cys Ala Gly Gly Thr Gly Gly Cys
1845 1850 1855
Cys Gly Thr Gly Cys Thr Gly Thr Ala Cys Cys Ala Gly Gly Ala Cys
1860 1865 1870
Gly Thr Gly Ala Ala Cys Thr Gly Cys Ala Cys Cys Gly Ala Gly Gly
1875 1880 1885
Thr Gly Cys Cys Cys Gly Thr Gly Gly Cys Cys Ala Thr Cys Cys Ala
1890 1895 1900
Cys Gly Cys Cys Gly Ala Cys Cys Ala Gly Cys Thr Gly Ala Cys Cys
1905 1910 1915 1920
Cys Cys Cys Ala Cys Cys Thr Gly Gly Cys Gly Cys Gly Thr Gly Thr
1925 1930 1935
Ala Cys Thr Cys Cys Ala Cys Cys Gly Gly Cys Thr Cys Cys Ala Ala
1940 1945 1950
Cys Gly Thr Gly Thr Thr Cys Cys Ala Gly Ala Cys Cys Cys Gly Cys
1955 1960 1965
Gly Cys Cys Gly Gly Cys Thr Gly Cys Cys Thr Gly Ala Thr Cys Gly
1970 1975 1980
Gly Cys Gly Cys Cys Gly Ala Gly Cys Ala Cys Gly Thr Gly Ala Ala
1985 1990 1995 2000
Cys Ala Ala Cys Thr Cys Cys Thr Ala Cys Gly Ala Gly Thr Gly Cys
2005 2010 2015
Gly Ala Cys Ala Thr Cys Cys Cys Cys Ala Thr Cys Gly Gly Cys Gly
2020 2025 2030
Cys Cys Gly Gly Cys Ala Thr Cys Thr Gly Cys Gly Cys Cys Thr Cys
2035 2040 2045
Cys Thr Ala Cys Cys Ala Gly Ala Cys Cys Cys Ala Gly Ala Cys Cys
2050 2055 2060
Ala Ala Cys Thr Cys Cys Cys Cys Cys Thr Cys Cys Gly Thr Gly Gly
2065 2070 2075 2080
Cys Cys Thr Cys Cys Cys Ala Gly Thr Cys Cys Ala Thr Cys Ala Thr
2085 2090 2095
Cys Gly Cys Cys Thr Ala Cys Ala Cys Cys Ala Thr Gly Thr Cys Cys
2100 2105 2110
Cys Thr Gly Gly Gly Cys Gly Cys Cys Gly Ala Gly Ala Ala Cys Thr
2115 2120 2125
Cys Cys Gly Thr Gly Gly Cys Cys Thr Ala Cys Thr Cys Cys Ala Ala
2130 2135 2140
Cys Ala Ala Cys Thr Cys Cys Ala Thr Cys Gly Cys Cys Ala Thr Cys
2145 2150 2155 2160
Cys Cys Cys Ala Cys Cys Ala Ala Cys Thr Thr Cys Ala Cys Cys Ala
2165 2170 2175
Thr Cys Thr Cys Cys Gly Thr Gly Ala Cys Cys Ala Cys Cys Gly Ala
2180 2185 2190
Gly Ala Thr Cys Cys Thr Gly Cys Cys Cys Gly Thr Gly Thr Cys Cys
2195 2200 2205
Ala Thr Gly Ala Cys Cys Ala Ala Gly Ala Cys Cys Thr Cys Cys Gly
2210 2215 2220
Thr Gly Gly Ala Cys Thr Gly Cys Ala Cys Cys Ala Thr Gly Thr Ala
2225 2230 2235 2240
Cys Ala Thr Cys Thr Gly Cys Gly Gly Cys Gly Ala Cys Thr Cys Cys
2245 2250 2255
Ala Cys Cys Gly Ala Gly Thr Gly Cys Thr Cys Cys Ala Ala Cys Cys
2260 2265 2270
Thr Gly Cys Thr Gly Cys Thr Gly Cys Ala Gly Thr Ala Cys Gly Gly
2275 2280 2285
Cys Thr Cys Cys Thr Thr Cys Thr Gly Cys Ala Cys Cys Cys Ala Gly
2290 2295 2300
Cys Thr Gly Ala Ala Cys Cys Gly Cys Gly Cys Cys Cys Thr Gly Ala
2305 2310 2315 2320
Cys Cys Gly Gly Cys Ala Thr Cys Gly Cys Cys Gly Thr Gly Gly Ala
2325 2330 2335
Gly Cys Ala Gly Gly Ala Cys Ala Ala Gly Ala Ala Cys Ala Cys Cys
2340 2345 2350
Cys Ala Gly Gly Ala Gly Gly Thr Gly Thr Thr Cys Gly Cys Cys Cys
2355 2360 2365
Ala Gly Gly Thr Gly Ala Ala Gly Cys Ala Gly Ala Thr Cys Thr Ala
2370 2375 2380
Cys Ala Ala Gly Ala Cys Cys Cys Cys Cys Cys Cys Cys Ala Thr Cys
2385 2390 2395 2400
Ala Ala Gly Gly Ala Cys Thr Thr Cys Gly Gly Cys Gly Gly Cys Thr
2405 2410 2415
Thr Cys Ala Ala Cys Thr Thr Cys Thr Cys Cys Cys Ala Gly Ala Thr
2420 2425 2430
Cys Cys Thr Gly Cys Cys Cys Gly Ala Cys Cys Cys Cys Thr Cys Cys
2435 2440 2445
Ala Ala Gly Cys Cys Cys Thr Cys Cys Ala Ala Gly Cys Gly Cys Thr
2450 2455 2460
Cys Cys Thr Thr Cys Ala Thr Cys Gly Ala Gly Gly Ala Cys Cys Thr
2465 2470 2475 2480
Gly Cys Thr Gly Thr Thr Cys Ala Ala Cys Ala Ala Gly Gly Thr Gly
2485 2490 2495
Ala Cys Cys Cys Thr Gly Gly Cys Cys Gly Ala Cys Gly Cys Cys Gly
2500 2505 2510
Gly Cys Thr Thr Cys Ala Thr Cys Ala Ala Gly Cys Ala Gly Thr Ala
2515 2520 2525
Cys Gly Gly Cys Gly Ala Cys Thr Gly Cys Cys Thr Gly Gly Gly Cys
2530 2535 2540
Gly Ala Cys Ala Thr Cys Gly Cys Cys Gly Cys Cys Cys Gly Cys Gly
2545 2550 2555 2560
Ala Cys Cys Thr Gly Ala Thr Cys Thr Gly Cys Gly Cys Cys Cys Ala
2565 2570 2575
Gly Ala Ala Gly Thr Thr Cys Ala Ala Cys Gly Gly Cys Cys Thr Gly
2580 2585 2590
Ala Cys Cys Gly Thr Gly Cys Thr Gly Cys Cys Cys Cys Cys Cys Cys
2595 2600 2605
Thr Gly Cys Thr Gly Ala Cys Cys Gly Ala Cys Gly Ala Gly Ala Thr
2610 2615 2620
Gly Ala Thr Cys Gly Cys Cys Cys Ala Gly Thr Ala Cys Ala Cys Cys
2625 2630 2635 2640
Thr Cys Cys Gly Cys Cys Cys Thr Gly Cys Thr Gly Gly Cys Cys Gly
2645 2650 2655
Gly Cys Ala Cys Cys Ala Thr Cys Ala Cys Cys Thr Cys Cys Gly Gly
2660 2665 2670
Cys Thr Gly Gly Ala Cys Cys Thr Thr Cys Gly Gly Cys Gly Cys Cys
2675 2680 2685
Gly Gly Cys Gly Cys Cys Gly Cys Cys Cys Thr Gly Cys Ala Gly Ala
2690 2695 2700
Thr Cys Cys Cys Cys Thr Thr Cys Gly Cys Cys Ala Thr Gly Cys Ala
2705 2710 2715 2720
Gly Ala Thr Gly Gly Cys Cys Thr Ala Cys Cys Gly Cys Thr Thr Cys
2725 2730 2735
Ala Ala Cys Gly Gly Cys Ala Thr Cys Gly Gly Cys Gly Thr Gly Ala
2740 2745 2750
Cys Cys Cys Ala Gly Ala Ala Cys Gly Thr Gly Cys Thr Gly Thr Ala
2755 2760 2765
Cys Gly Ala Gly Ala Ala Cys Cys Ala Gly Ala Ala Gly Cys Thr Gly
2770 2775 2780
Ala Thr Cys Gly Cys Cys Ala Ala Cys Cys Ala Gly Thr Thr Cys Ala
2785 2790 2795 2800
Ala Cys Thr Cys Cys Gly Cys Cys Ala Thr Cys Gly Gly Cys Ala Ala
2805 2810 2815
Gly Ala Thr Cys Cys Ala Gly Gly Ala Cys Thr Cys Cys Cys Thr Gly
2820 2825 2830
Thr Cys Cys Thr Cys Cys Ala Cys Cys Gly Cys Cys Thr Cys Cys Gly
2835 2840 2845
Cys Cys Cys Thr Gly Gly Gly Cys Ala Ala Gly Cys Thr Gly Cys Ala
2850 2855 2860
Gly Gly Ala Cys Gly Thr Gly Gly Thr Gly Ala Ala Cys Cys Ala Gly
2865 2870 2875 2880
Ala Ala Cys Gly Cys Cys Cys Ala Gly Gly Cys Cys Cys Thr Gly Ala
2885 2890 2895
Ala Cys Ala Cys Cys Cys Thr Gly Gly Thr Gly Ala Ala Gly Cys Ala
2900 2905 2910
Gly Cys Thr Gly Thr Cys Cys Thr Cys Cys Ala Ala Cys Thr Thr Cys
2915 2920 2925
Gly Gly Cys Gly Cys Cys Ala Thr Cys Thr Cys Cys Thr Cys Cys Gly
2930 2935 2940
Thr Gly Cys Thr Gly Ala Ala Cys Gly Ala Cys Ala Thr Cys Cys Thr
2945 2950 2955 2960
Gly Thr Cys Cys Cys Gly Cys Cys Thr Gly Gly Ala Cys Ala Ala Gly
2965 2970 2975
Gly Thr Gly Gly Ala Gly Gly Cys Cys Gly Ala Gly Gly Thr Gly Cys
2980 2985 2990
Ala Gly Ala Thr Cys Gly Ala Cys Cys Gly Cys Cys Thr Gly Ala Thr
2995 3000 3005
Cys Ala Cys Cys Gly Gly Cys Cys Gly Cys Cys Thr Gly Cys Ala Gly
3010 3015 3020
Thr Cys Cys Cys Thr Gly Cys Ala Gly Ala Cys Cys Thr Ala Cys Gly
3025 3030 3035 3040
Thr Gly Ala Cys Cys Cys Ala Gly Cys Ala Gly Cys Thr Gly Ala Thr
3045 3050 3055
Cys Cys Gly Cys Gly Cys Cys Gly Cys Cys Gly Ala Gly Ala Thr Cys
3060 3065 3070
Cys Gly Cys Gly Cys Cys Thr Cys Cys Gly Cys Cys Ala Ala Cys Cys
3075 3080 3085
Thr Gly Gly Cys Cys Gly Cys Cys Ala Cys Cys Ala Ala Gly Ala Thr
3090 3095 3100
Gly Thr Cys Cys Gly Ala Gly Thr Gly Cys Gly Thr Gly Cys Thr Gly
3105 3110 3115 3120
Gly Gly Cys Cys Ala Gly Thr Cys Cys Ala Ala Gly Cys Gly Cys Gly
3125 3130 3135
Thr Gly Gly Ala Cys Thr Thr Cys Thr Gly Cys Gly Gly Cys Ala Ala
3140 3145 3150
Gly Gly Gly Cys Thr Ala Cys Cys Ala Cys Cys Thr Gly Ala Thr Gly
3155 3160 3165
Thr Cys Cys Thr Thr Cys Cys Cys Cys Cys Ala Gly Thr Cys Cys Gly
3170 3175 3180
Cys Cys Cys Cys Cys Cys Ala Cys Gly Gly Cys Gly Thr Gly Gly Thr
3185 3190 3195 3200
Gly Thr Thr Cys Cys Thr Gly Cys Ala Cys Gly Thr Gly Ala Cys Cys
3205 3210 3215
Thr Ala Cys Gly Thr Gly Cys Cys Cys Gly Cys Cys Cys Ala Gly Gly
3220 3225 3230
Ala Gly Ala Ala Gly Ala Ala Cys Thr Thr Cys Ala Cys Cys Ala Cys
3235 3240 3245
Cys Gly Cys Cys Cys Cys Cys Gly Cys Cys Ala Thr Cys Thr Gly Cys
3250 3255 3260
Cys Ala Cys Gly Ala Cys Gly Gly Cys Ala Ala Gly Gly Cys Cys Cys
3265 3270 3275 3280
Ala Cys Thr Thr Cys Cys Cys Cys Cys Gly Cys Gly Ala Gly Gly Gly
3285 3290 3295
Cys Gly Thr Gly Thr Thr Cys Gly Thr Gly Thr Cys Cys Ala Ala Cys
3300 3305 3310
Gly Gly Cys Ala Cys Cys Cys Ala Cys Thr Gly Gly Thr Thr Cys Gly
3315 3320 3325
Thr Gly Ala Cys Cys Cys Ala Gly Cys Gly Cys Ala Ala Cys Thr Thr
3330 3335 3340
Cys Thr Ala Cys Gly Ala Gly Cys Cys Cys Cys Ala Gly Ala Thr Cys
3345 3350 3355 3360
Ala Thr Cys Ala Cys Cys Ala Cys Cys Gly Ala Cys Ala Ala Cys Ala
3365 3370 3375
Cys Cys Thr Thr Cys Gly Thr Gly Thr Cys Cys Gly Gly Cys Ala Ala
3380 3385 3390
Cys Thr Gly Cys Gly Ala Cys Gly Thr Gly Gly Thr Gly Ala Thr Cys
3395 3400 3405
Gly Gly Cys Ala Thr Cys Gly Thr Gly Ala Ala Cys Ala Ala Cys Ala
3410 3415 3420
Cys Cys Gly Thr Gly Thr Ala Cys Gly Ala Cys Cys Cys Cys Cys Thr
3425 3430 3435 3440
Gly Cys Ala Gly Cys Cys Cys Gly Ala Gly Cys Thr Gly Gly Ala Cys
3445 3450 3455
Thr Cys Cys Thr Thr Cys Ala Ala Gly Gly Ala Gly Gly Ala Gly Cys
3460 3465 3470
Thr Gly Gly Ala Cys Ala Ala Gly Thr Ala Cys Thr Thr Cys Ala Ala
3475 3480 3485
Gly Ala Ala Cys Cys Ala Cys Ala Cys Cys Thr Cys Cys Cys Cys Cys
3490 3495 3500
Gly Ala Cys Gly Thr Gly Gly Ala Cys Cys Thr Gly Gly Gly Cys Gly
3505 3510 3515 3520
Ala Cys Ala Thr Cys Thr Cys Cys Gly Gly Cys Ala Thr Cys Ala Ala
3525 3530 3535
Cys Gly Cys Cys Thr Cys Cys Gly Thr Gly Gly Thr Gly Ala Ala Cys
3540 3545 3550
Ala Thr Cys Cys Ala Gly Ala Ala Gly Gly Ala Gly Ala Thr Cys Gly
3555 3560 3565
Ala Cys Cys Gly Cys Cys Thr Gly Ala Ala Cys Gly Ala Gly Gly Thr
3570 3575 3580
Gly Gly Cys Cys Ala Ala Gly Ala Ala Cys Cys Thr Gly Ala Ala Cys
3585 3590 3595 3600
Gly Ala Gly Thr Cys Cys Cys Thr Gly Ala Thr Cys Gly Ala Cys Cys
3605 3610 3615
Thr Gly Cys Ala Gly Gly Ala Gly Cys Thr Gly Gly Gly Cys Ala Ala
3620 3625 3630
Gly Thr Ala Cys Gly Ala Gly Cys Ala Gly Thr Ala Cys Ala Thr Cys
3635 3640 3645
Ala Ala Gly Thr Gly Gly Cys Cys Cys Thr Gly Gly Thr Ala Cys Ala
3650 3655 3660
Thr Cys Thr Gly Gly Cys Thr Gly Gly Gly Cys Thr Thr Cys Ala Thr
3665 3670 3675 3680
Cys Gly Cys Cys Gly Gly Cys Cys Thr Gly Ala Thr Cys Gly Cys Cys
3685 3690 3695
Ala Thr Cys Gly Thr Gly Ala Thr Gly Gly Thr Gly Ala Cys Cys Ala
3700 3705 3710
Thr Cys Ala Thr Gly Cys Thr Gly Thr Gly Cys Thr Gly Cys Ala Thr
3715 3720 3725
Gly Ala Cys Cys Thr Cys Cys Thr Gly Cys Thr Gly Cys Thr Cys Cys
3730 3735 3740
Thr Gly Cys Cys Thr Gly Ala Ala Gly Gly Gly Cys Thr Gly Cys Thr
3745 3750 3755 3760
Gly Cys Thr Cys Cys Thr Gly Cys Gly Gly Cys Thr Cys Cys Thr Gly
3765 3770 3775
Cys Thr Gly Cys Ala Ala Gly Thr Thr Cys Gly Ala Cys Gly Ala Gly
3780 3785 3790
Gly Ala Cys Gly Ala Cys Thr Cys Cys Gly Ala Gly Cys Cys Cys Gly
3795 3800 3805
Thr Gly Cys Thr Gly Ala Ala Gly Gly Gly Cys Gly Thr Gly Ala Ala
3810 3815 3820
Gly Cys Thr Gly Cys Ala Cys Thr Ala Cys Ala Cys Cys Thr Ala Ala
3825 3830 3835 3840
<210> 7
<211> 3852
<212> PRT
<213> 重组核苷酸()
<400> 7

Claims (10)

1.一种重组新城疫病毒疫苗组合物，所述疫苗组合物包括由病毒载体编码改造的SARS-CoV-2的刺突蛋白(SA)，所述病毒载体为新城疫病毒LaSota弱毒株,该改造的SARS-CoV-2的刺突蛋白(SA)包含来自SEQ ID NO：1的氨基酸序列。
2.一种重组新城疫病毒疫苗组合物，所述疫苗组合物包括由病毒载体编码改造的SARS-CoV-2的刺突蛋白(SB)，所述病毒载体为新城疫病毒LaSota弱毒株,该改造的SARS-CoV-2的刺突蛋白(SB)包含来自SEQ ID NO：2的氨基酸序列。
3.一种重组新城疫病毒疫苗组合物，所述疫苗组合物包括由病毒载体编码改造的SARS-CoV-2的刺突蛋白(S6PA)，所述病毒载体为新城疫病毒LaSota弱毒株,该改造的SARS-CoV-2的刺突蛋白(S6PA)包含来自SEQ ID NO：3的氨基酸序列。
4.一种重组新城疫病毒疫苗组合物，所述疫苗组合物包括由病毒载体编码改造的SARS-CoV-2的刺突蛋白(S6PB)，所述病毒载体为新城疫病毒LaSota弱毒株,该改造的SARS-CoV-2的刺突蛋白(S6PB)包含来自SEQ ID NO：4的氨基酸序列。
5.一种嵌合核酸分子，其包含编码新城疫病毒LaSota弱毒株的核酸分子和编码改造的SARS-CoV-2的刺突蛋白(SA)的核酸分子，所述改造的SARS-CoV-2的刺突蛋白(SA)的核酸分子包含来自SEQ ID NO：5的核酸序列。
6.一种嵌合核酸分子，其包含编码新城疫病毒LaSota弱毒株的核酸分子和编码改造的SARS-CoV-2的刺突蛋白(SB)的核酸分子，所述改造的SARS-CoV-2的刺突蛋白(SB)的核酸分子包含来自SEQ ID NO：6的核酸序列。
7.一种嵌合核酸分子，其包含编码新城疫病毒LaSota弱毒株的核酸分子和编码改造的SARS-CoV-2的刺突蛋白(S6PA)的核酸分子，所述改造的SARS-CoV-2的刺突蛋白(S6PA)的核酸分子包含来自SEQ ID NO：7的核酸序列。
8.一种嵌合核酸分子，其包含编码新城疫病毒LaSota弱毒株的核酸分子和编码改造的SARS-CoV-2的刺突蛋白(S6PB)的核酸分子，所述改造的SARS-CoV-2的刺突蛋白(S6PB)的核酸分子包含来自SEQ ID NO：8的核酸序列。
9.如权利要求1-4任一项所述的疫苗组合物，疫苗是口服疫苗和/或亚单位疫苗。
10.如权利要求1-4任一项所述的疫苗组合物，该疫苗组合物还可以包含至少一种额外的抗原，至少一种额外的抗原保护性地抵御可以引起哺乳动物疾病的微生物。
CN202110628521.1A 2021-06-07 2021-06-07 新型冠状病毒肺炎的重组新城疫病毒疫苗 Active CN113913393B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202110628521.1A CN113913393B (zh) 2021-06-07 2021-06-07 新型冠状病毒肺炎的重组新城疫病毒疫苗

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202110628521.1A CN113913393B (zh) 2021-06-07 2021-06-07 新型冠状病毒肺炎的重组新城疫病毒疫苗

Publications (2)

Publication Number Publication Date
CN113913393A true CN113913393A (zh) 2022-01-11
CN113913393B CN113913393B (zh) 2023-05-09

Family

ID=79232796

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202110628521.1A Active CN113913393B (zh) 2021-06-07 2021-06-07 新型冠状病毒肺炎的重组新城疫病毒疫苗

Country Status (1)

Country Link
CN (1) CN113913393B (zh)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1490056A (zh) * 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
CN111218459A (zh) * 2020-03-18 2020-06-02 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
CN112831523A (zh) * 2021-03-16 2021-05-25 厦门宝太生物科技有限公司 一种SARS-CoV-2-RBD真核蛋白表达载体及其制备方法和用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1490056A (zh) * 2002-10-18 2004-04-21 ��¡���ɵ°��̲��о����� 针对hiv-1的免疫方法和组合物
CN111218459A (zh) * 2020-03-18 2020-06-02 中国人民解放军军事科学院军事医学研究院 一种以人复制缺陷腺病毒为载体的重组新型冠状病毒疫苗
CN112831523A (zh) * 2021-03-16 2021-05-25 厦门宝太生物科技有限公司 一种SARS-CoV-2-RBD真核蛋白表达载体及其制备方法和用途

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CHING-LIN HSIEH 等: "Structure-based Design of Prefusion-stabilized SARS-CoV-2 Spikes", 《PREPRINT》 *
RINKE BOS 等: "Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses", 《VACCINES》 *
WEINA SUN 等: "Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate", 《EBIOMEDICINE》 *

Also Published As

Publication number Publication date
CN113913393B (zh) 2023-05-09

Similar Documents

Publication Publication Date Title
JP5153984B2 (ja) 口蹄疫に対するワクチン
CN113444156B (zh) 新型冠状病毒肺炎重组人5型腺病毒疫苗
EP3394085B1 (en) Feline calicivirus vaccine
CN107250353B (zh) 二价猪流感病毒疫苗
JP2003529323A (ja) ブタシルコウイルス組換えポックスウイルスワクチン
HU211548A9 (en) Expression of specific immunogens using viral antigens
JP2003529323A5 (zh)
CN113201507B (zh) 一种重组的伪狂犬病病毒及其疫苗组合物
CN113666990A (zh) 一种诱导广谱抗冠状病毒的t细胞疫苗免疫原及其应用
KR102236137B1 (ko) 수포성 구내염 바이러스의 변형된 기질 단백질
US20150132332A1 (en) Anti-HIV Vaccine Constructed Based on Amino Acid Mutations in Attenuated Live EIAV Vaccine
CN109310750B (zh) 编码传染性喉气管炎病毒和传染性法氏囊病病毒抗原的重组非致病性马立克氏病病毒构建体
CN113336838B (zh) 新型冠状病毒肺炎重组痘苗病毒载体疫苗
JP4691495B2 (ja) コロナウイルススパイクｓ１融合蛋白及びその発現ベクター
CN116284272B (zh) 一种广谱抗牛科病毒性腹泻病毒的mRNA疫苗及其应用
CN113913393B (zh) 新型冠状病毒肺炎的重组新城疫病毒疫苗
US20230233670A1 (en) A Recombinant Modified Vaccinia Virus (MVA) Vaccine Against Coronavirus Disease
CN113278634B (zh) 一种预防和治疗默克尔细胞癌的新型疫苗
CN117003885A (zh) H5n8禽流感广谱性疫苗的开发及其应用
CN109022373A (zh) 鸭瘟病毒ul56基因3’端缺失和lorf5基因缺失突变株及其构建方法与应用
JP2023545524A (ja) 組換えｈｖｔ及びその使用
KR20220097422A (ko) 치쿤구니야 바이러스 유사 입자 백신 및 이의 사용 방법
WO2000020600A1 (en) Avian pneumovirus vaccine and diagnostic agent
JP7137276B2 (ja) 血清型ａ口蹄疫ウイルス用モザイクワクチン
CN115040644B (zh) 新冠肺炎重组狂犬病病毒载体疫苗

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant